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ABBREVIATIONS 
AML: Acute Myeloid Leukemia  
APP: Amyloid Precursor Protein  
Ara-C: 1-β-D-arabinofuranosylcytosine or cytosine arabinoside  
BFU-E: Burst-Forming Unit Erythroid  
BSA: Bovine Serum Albumin 
CEN: Core Erythroid Network 
CFU-E: Colony-Forming Unit Erythroid  
ChIA-PET: Chromatin Interaction Analysis by Paired-End Tag Sequencing 
ChIP: Chromatin Immunoprecipitation  
ChIP-seq: Chromatin Immunoprecipitation followed by sequencing  
CML: Chronic Myeloid Leukemia 
CpG: Cytosine-phosphate-Guanine  
CTCF: CCCTC-binding factor 
CTS: CTCF binding (or target) site 
DMEM: Dubelcco´s Modified Eagle Medium 
DMSO: Dimethyl Sulfoxide 
EDTA: Ethylenediaminetetraacetic acid 
ENCODE: Encyclopedia of DNA Elements  
Epo: Erythropoietin  
EpoR: Erythropoietin Receptor  
EV: Empty Vector  
FBS: Fetal Bovine Serum  
FLI1: Friend Leukemia Integration 1  
Fw: Forward  
GATA: GATA-binding factor 
Hb: Hemoglobin  
HEY1: Hairy/enhancer-of-split related with YRPW motif protein 1 
HSC: Hematopoietic Stem Cell  
KLF1: Krüppel-like factor 1  
LDB1: LIM-Domain-Binding protein 1 
LMO2: LIM Domain Only 2 
MEP: Megakaryocyte Erythroid Progenitor  
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MOI: Multiplicity of Infection  
MYB: Myeloblastosis oncogene 
NFE2L2: Nuclear Factor, Erythroid like 2 
PARP1: Poly(ADP-ribose) Polymerase 1 
PARylation: Poly(ADP-ribosyl)ation 
PBS: Phosphate-buffered saline 
PEG: Polyethylene glycol  
PEI: Polyethylenimine 
PTM: Post-translational Modification  
RBC: Red Blood Cell 
RPMI: Culture medium Roswell Park Memorial Institute 
RT: Room Temperature  
RT-qPCR: Quantitative Real-Time Polymerase Chain Reaction  
Rv: Reverse 
SCF: Stem Cell Factor 
SCL: Stem Cell Leukemia 
s.d.: Standard Deviation  
SDS: Sodium Dodecyl Sulfate 
SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
shCTCF: Short hairpin RNA against CTCF 
shRNA: Short hairpin RNA 
TAD: Topologically Associated Domain  
TAL1: T-cell Acute Lymphocytic Leukemia 1  
TCF3: Transcription Factor 3  
TF: Transcription Factor 
TSS: Transcription Start Site 
UCSC: University of California, Santa Cruz 
ZN: Zinc-Finger 
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ABSTRACT 
 CCCTC-binding factor (CTCF) is a zinc finger protein that binds to many DNA 
sequences and interacts with several partners to perform multiple functions, including 
transcriptional regulation, chromatin insulation, epigenetic modulation, and long-range 
interactions. Red blood cells are generated from hematopoietic stem cells during the 
erythropoiesis. Previous results of our group revealed that CTCF is involved in this process. The 
aim of this study was to better know the role of CTCF in the control of erythropoiesis and in the 
regulation of specific erythroid transcription factors. CTCF was downregulated using shRNA in 
K562 cells, derived from human chronic myeloid leukemia, and in primary CD34+ progenitor 
cells purified from cord blood. Erythroid differentiation was induced by Ara-C or Imatinib in 
K562 cells and by erythropoietin in CD34+ cells. Expression of erythroid markers and 
transcription factors was analyzed by Western blot and RT-qPCR. We observed that CTCF 
downregulation inhibits erythroid differentiation and regulates the expression of specific 
erythroid transcription factors. Using the ENCODE project, we identified CTCF binding sites to 
the regulatory regions of selected erythroid transcription factors and the chromatin interactions 
mediated by CTCF around them, which vary across cell lines. Moreover, we analyzed the histone 
modifications in the CTCF binding sites to erythroid genes. Furthermore, we analyzed clinical 
profiles from cBioPortal, and we observed that genetic alterations in CTCF gene appear to be 
involved in the development of acute myeloid leukemia, which supports CTCF role as tumor 
suppressor gene. In conclusion, our data suggest that CTCF plays an essential role in the erythroid 
differentiation through the formation of long-range chromatin interactions that modulate the 
expression of erythroid transcription factors. 
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1. INTRODUCTION 
1.1. CTCF STRUCTURE AND GENERAL FEATURES 
The multifunctional CCCTC-binding factor (CTCF) is a highly conserved DNA-binding protein 
with 11-zinc-finger (ZF) domain. CTCF was firstly described for the presence of the repeating CCCTC 
sequence in its DNA binding site at the chicken c-Myc gene 5´-flanking sequence (Lobanenkov et al., 
1990). Then, CTCF was characterized as a transcriptional repressor of chicken Myc gene (Klenova et al., 
1993) and of human MYC gene (Filippova et al., 1996). Shortly after, CTCF was described as a 
transcriptional activator of the amyloid β-precursor protein (APP) (Vostrov & Quitschke, 1997). 
Furthermore, negative protein 1 (NeP1) was described as a binding protein of the silencer element of the 
chicken lysozyme that synergistically with the thyroid hormone receptor represses transcriptional activity 
(Baniahmad et al., 1990). Soon after, NeP1 was turned out to be CTCF in many organisms, including 
humans, which reveals the role of CTCF in the organization of chromatin structure (Burcin et al., 1997).  
CTCF levels markedly impact cellular functions, such as differentiation, proliferation and 
apoptosis, at least in part, by regulating gene expression (Torrano et al., 2005). CTCF is encoded by a 
single-copy gene localized at chromosome locus 16q22.1 (Filippova et al., 1998). The mammalian CTCF 
gene has 5 introns and 10 exons. Exons E1 and E10 encode transcriptional repressor domains, exons E2 to 
E8 encode 11 ZFs and E9 encodes an AT-rich DNA-binding motif (Ohlsson et al., 2001). The CTCF gene 
is cell-cycle-regulated, with a maximum expression at S-G2 phase (Klenova et al., 1998). Additionally, 
CTCF associates with the nuclear matrix, with the centrosomes and the midbody at the end of mitosis, 
suggesting that CTCF plays a role in cell-cycle control (Rosa-Garrido et al., 2012; Zhang et al., 2004).  
In adult organisms, CTCF protein is ubiquitously expressed and localized in the nuclei. The 
nucleolar localization of CTCF regulating ribosomal genes expression has also been reported (Torrano et 
al., 2006; Van De Nobelen et al., 2010). CTCF is present at 80,000 sites on mammalian chromosomes 
(Hashimoto et al., 2017) and 50,000 CTCF binding sites can be found in a single cell line (Wang et al., 
2012). CTCF is remarkably evolutionary conserved among bilaterians, being 100% identical in the ZF 
domain (Filippova et al., 1996), and phylogenetic analysis suggest an early origin in the evolution of 
Metazoa (Arzate-Mejía et al., 2018; Heger et al., 2012). Expression levels and nuclear distribution patterns 
vary in a cell type-specific manner, indicating an important role in phenotypic diversity and gene expression 
patterns (Phillips & Corces, 2009). The differences in the affinity of CTCF binding sites are related to their 
conservation between species and tissues. Generally, low occupancy sites tend to exhibit higher expression 
and are cell-specific, while high occupancy sites are associated with repressive histone marks and appear 
to be conserved across cell types (Essien et al., 2009).  
CTCF is a single polypeptide chain of 727 amino acid residues, with a molecular weight of 130 
kDa, that folds into a secondary structure with three domains: a N-terminal region, a central domain 
containing 11 ZFs, each one consisting of an α-helix and two parallel β strands (Figure 1.1), and a C-
terminal region (Zlatanova & Caiafa, 2009). The first 10 fingers are C2H2-type ZFs, which are typical units 
of ~30 residues containing a pair of cysteine residues separated by 12 amino acids from a pair of histidines. 
These four residues are coordinated through a Zn atom to form a compact structure with a DNA-recognition 
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α-helix (Ohlsson et al., 2001). In vertebrates, the eleventh C-terminal ZF is C2HC-type ZF and reassembles 
the C2H2 fingers in structure (Guo et al., 2018). The C-terminal and N-terminal CTCF domains exhibit 
repressor activities (Filippova et al., 1996). The ZF region is the major DNA binding region, although both 
N- and C-terminal regions of CTCF have the ability to weakly interact with the DNA (Guo et al., 2018). 
The three domains contain sites for distinct post-translational modifications (PTMs), which can 
modulate CTCF activity: poly(ADP-ribosyl)ation (PARylation) in the N-terminal domain confers insulator 
properties to CTCF and is involved in the control of ribosomal gene expression (Yu et al., 2004; Zlatanova 
& Caiafa, 2009), the C-terminal domain contains several sites for phosphorylation, more specifically 
phosphorylation of Ser612 switches CTCF to an activator of the chicken Myc (Klenova et al., 2001), and 
SUMOylation at two sites in the polypeptide chain contributes to the repressive function of CTCF on the 
Myc P2 promoter (MacPherson et al., 2009).  
1.2. CTCF BINDING TO DNA 
CTCF is a multivalent factor that can recognize and bind to different DNA sequences by 
employing different combinations of ZFs (Filippova et al., 1996), which is known as the “CTCF code” 
(Wang et al., 2019). However, the finger recognition patterns are not predictable based on the DNA 
sequences (Guo et al., 2018). CTCF binding sequences of ∼50–60 bp are termed CTCF binding (or target) 
sites (CTSs). More than 60% of CTSs are located in intergenic regions and sites upstream of the 
transcription start sites (TSS) (Lee et al., 2012), and only 20% of CTSs display promoter-proximal 
localization (Kim et al., 2007).  
Genome-wide data sets have enabled the identification of a 12-15 bp core consensus sequence (5´-
NCA-NNA-G(G/A)N-GGC-(G/A)(C/G)(T/C)-3´) that is remarkably conserved in al cell types (Hashimoto 
et al., 2017; Phillips & Corces, 2009). ZFs 4-7 bind to 80% of CTCF target sites containing the 15 bp core 
motif and ZF8 on its own stabilizes CTCF to core sequence (Nakahashi et al., 2013). Analysis of CTCF 
consensus binding sequences identified the 8 most conserved nucleotides in the 2nd, 3rd, 6th, 7th, 8th, 10th, 
11th, and 12th positions, which are recognized primarily by H-bonds between the bases of the top strand and 
residues of ZFs 4-7 (Hashimoto et al., 2017; Wang et al., 2019). Furthermore, CTCF tolerates base changes 
at specific positions within the degenerated CTSs sequences, permitting genome-wide CTCF binding to a 
diverse range of CTSs (Yin et al., 2017). 
The six fingers ZFs 2-7 interact with the major groove of DNA making specific contacts with 
nucleotides by amino acid side chains at positions -1, +2, +3 and +6 (Hashimoto et al., 2017; Ohlsson et 
al., 2001). Each ZF recognizes 3-4bp in the DNA and the protein sequence runs in the opposite direction 
(from C to N) to the 15 bp core sequence (5´→3´) (Hashimoto et al., 2017) (Figure 1.1). There is 
controversy about the binding of the ZFs 9-11 to the target DNA (Hashimoto et al., 2017; Yin et al., 2017). 
DNA motifs flanking the core sequence modulate CTCF binding by enhancing (upstream motif) or reducing 
(downstream motif) its affinity to DNA. The conserved upstream motif is bound by ZFs 9-11, while the 
downstream motif is bound by ZFs 1-2 (Nakahashi et al., 2013).  
Nuclear magnetic resonance (NMR) spectroscopy experiments revealed the mechanism of CTCF 
binding to the DNA. Before binding, individual ZFs are well structured with flexible linker regions. Then, 
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specific combinations of ZFs recognize DNA sequences and the other ZFs remain flexible, which may 
protrude out for further DNA binding. The flexibility of the inter-ZF linkers facilitates to CTCF adopt 
various conformations depending on the DNA sequences (Xu et al., 2018). A mutagenesis study has 
recently identified ineffective fingers and dominant effective fingers, which form distinctive patterns on 
different DNA targets (Guo et al., 2018).  
 
Figure 1.1. CTCF binding to DNA. ZFs 2-7 interact with the major groove of DNA. Each finger of ZFs 3–7 contacts 3 
bases of the 15-bp consensus sequence. ZF2 continues to follow in the major groove, but the side chains within the 
DNA-interacting helix were too far away to make base-specific hydrogen bonds. Adapted from Hashimoto et al., 2017. 
CTCF dimerization, this is the interaction of CTCF with another CTCF molecule via ZF and C-
terminal domains, has an important role in the interaction between distant DNA regions (Ohlsson et al., 
2010; Yusufzai et al., 2004). However, the dimerization through the N-terminal domain is not discarded 
(Yin et al., 2017). The surfaces available for dimerization vary depending on the underlying CTS (Ohlsson 
et al., 2010). Apart from dimerization, CTCF can interact with many partners, that will be detailed below. 
1.3. CTCF INTERACTING PARTNERS 
All 3 domains of CTCF may interact with other proteins (Chernukhin et al., 2007; Lee et al., 2017) 
or RNA (Saldaña-Meyer et al., 2019). More than 90 proteins were found to interact with CTCF with high 
confidence (Braccioli & de Wit, 2019), some of them bind to specific domains, but other interactions have 
not been mapped to specific domain (Figure 1.2). CTCF partners can be divided into several functional 
groups (Arzate-Mejía et al., 2018; Zlatanova & Caiafa, 2009): (i) architectural proteins: DNA 
topoisomerase II and cohesin, that has a great influence on CTCF function and will be detailed below; (ii) 
DNA-binding proteins: transcription factors and cofactors, including YB-1, YY1, Kaiso, RFX5, CIITA, 
OCT1, OCT4, TAF3, UBF; (iii) basal transcription: TFII-I and RNA Pol II; (iv) epigenetic modifiers and 
chromatin modelers: SIN3A, NURF, CDH8, BRD2, Suz12, Wdr5, DNMT1, H2A.Z, Taf1/SET, BRG1 and 
TET1; (v) miscellaneous: for example, RNA, PARP1, NPM, p68, LDB1 and CENP-E.  
Cohesin complex has a central role in holding the two sister chromatids in close contact from DNA 
replication to their separation. The cohesin complex comprises four subunits, formed by a Smc1-Smc3 
heterodimer that is complemented by Rad21/Scc1 and Scc3/SA1/SA2 subunits. The SA1 component 
directly interacts with CTCF (Steiner et al., 2016). There are two pools of cohesin at interphase (immobile 
and dynamic fractions) that form chromatin loops (Holwerda & de Laat, 2013). CTCF and cohesin have 
shared and independent functions at regulatory sequences in the genome. Interactions between cohesin and 
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CTCF mediate cell-type specific long-range chromatin contacts, modulate the enhancer-blocker activity of 
CTCF (Steiner et al., 2016) and can pause RNAPII activity, facilitating alternative splicing (Holwerda & 
de Laat, 2013). CTCF/cohesin binding sites consist of four modules defined as module 1-4 (Liu et al., 
2019). ZF3, ZFs 4-7 and ZFs 9-11 recognize module 4, 3-2 and module 1 respectively, while ZF8 
accommodates variable distances between modules 1 and 2 (Yin et al., 2017).  
 
Figure 1.2 CTCF-interacting partners with their binding domains. Not only DNA, but also multiple proteins interact 
with the ZF domain. Other partners interact with the C-terminal domain, other proteins interact with the N-terminal 
domain and several additional proteins interact with CTCF in unknown specific domains. 
1.4. CTCF FUNCTIONS 
 Transcription factor 
CTCF is one of the most studied transcription factors (TFs). CTCF functions as a classical 
transcription factor that activates (Vostrov & Quitschke, 1997) or represses (Burcin et al., 1997; Filippova 
et al., 1996; Klenova et al., 1993; Lobanenkov et al., 1990; Lutz, 2000) the transcription of its target genes. 
The interaction between CTCF and APP promoter can facilitate the transcription of APPβ gene (Vostrov 
& Quitschke, 1997). Regarding with transcriptional repression, CTCF was discovered as a repressor of 
MYC gene (Filippova et al., 1996; Klenova et al., 1993; Lobanenkov et al., 1990), and also inhibits the 
transcription of BAG-1 by interacting with its promoter (Sun et al., 2008). The transcription inhibition 
mediated by CTCF involves histone deacetylases and deacetylation of CTCF via binding the co-repressor 
SIN3 transcriptional regulator family member A (Lutz, 2000).  
 Insulator binding protein 
Chromatin insulators are DNA elements that prevent inappropriate interactions between 
neighboring genes and mediate both intra- and inter-chromosomal interactions (Ong & Corces, 2014). 
Insulators have two main functions: (1) enhancer-blocking insulators prevent enhancer-promoter 
interactions if placed between these elements, thus repressing transcription; and (2) chromatin barrier 
insulators prevent spreading of heterochromatin, a repressive chromatin environment, into neighboring 
active domains (Bushey et al., 2009).  
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CTCF functions as the only known chromatin insulator in vertebrates that prevents interaction 
between a promoter and nearby enhancers or silencers, thereby preventing inappropriate gene activation or 
silencing and establishing independently regulated chromatin domains (Arzate-Mejía et al., 2018; Ong & 
Corces, 2014; Wallace & Felsenfeld, 2007). The role of CTCF as enhancer-blocking insulator was firstly 
described for the chicken HS4 element in the 5´ boundary of the β globin locus (Bell et al., 1999), at the 
H19 imprinting control region (ICR) (Kanduri et al., 2000). In the case of the β globin locus, CTCF binding 
to the 5´HS4 insulator element also acts as a barrier to the spread of chromosomal silencing (West et al., 
2004). The role of CTCF as chromatin barrier insulator is linked to its function as epigenetic remodeling, 
that will be further explained.  
 Epigenetic regulator 
Epigenetics plays an important role in normal development and disease including cancer. The 
epigenetic modifications of histones are versatile marks that are involved in the regulation of gene 
expression. Methylation of histone H3 at lysine 4 (H3K4) is associated with transcriptionally active and/or 
poised genes in euchromatic regions of the genome. More specifically, H3K4me1 is a marker of enhancer 
elements and H3K4me3 is a marker of active promoter regions. Trimethylation of histone H3 at lysine 27 
(H3K27me3) is a repressive epigenetic mark of enhancer elements (Chen & Lodish, 2014). Acetylation of 
histone H3 at lysine 9 (H3K9Ac) is associated with transcriptionally active genes, while its methylation is 
associated with inactive genes (Mahajan et al., 2009).  
CTCF is involved in many aspects of epigenetic regulation, such as DNA methylation, high order 
chromatin structure and lineage-specific gene expression (Phillips & Corces, 2009). The role of CTCF as 
epigenetic regulator was firstly characterized by the ability of CTCF to compensate epigenetic silencing 
events in the human RB gene promoter (De La Rosa-Velázquez et al., 2007) and to protect the p53 gene 
promoter against repressive histone marks (Soto-Reyes & Recillas-Targa, 2010). Our group described how 
CTCF regulates the local epigenetic state of ribosomal DNA repeats (Van De Nobelen et al., 2010) and its 
role in the epigenetic regulation of BCL6 in B cells lymphoma (Batlle-López et al., 2015). 
CTCF binding can prevent the spreading of cytosine-phosphate-guanine (CpG) methylation and 
protect nearby promoters from silencing by keeping them free of DNA methylation in a tissue-specific 
manner (De La Rosa-Velázquez et al., 2007; Filippova et al., 2005). Moreover, CTCF consensus binding 
sequences contain CpG susceptible to DNA methylation and CpG methylation prevents CTCF binding, 
which preferentially binds to unmethylated sequences (De La Rosa-Velázquez et al., 2007; Kanduri et al., 
2000). CTCF binding is associated with chromatin boundaries by preventing the spread of repressive 
heterochromatin (chromatin barrier function) (Chen et al., 2012). Loss of CTCF binding is associated with 
the spread of heterochromatin and regional CpG methylation at CTCF binding sites (Cho et al., 2005). As 
an example, CTCF binding at the human MYC locus is required for protection from DNA methylation, 
which would lead to progressive loss of transcriptional activity (Gombert & Krumm, 2009). 
A portion of CTCF binding sites is found enriched at transitions between active chromatin (high 
in H2K5Ac) and inactive chromatin domains (high in H3K27me3) (Cuddapah et al., 2009). CTCF binding 
events at promoters tend to be conserved across tissues, whereas CTCF binding to enhancers is more tissue 
restricted (Holwerda & de Laat, 2013). Additionally, CTCF plays a key role in establishing local 
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heterochromatin structure at repetitive elements. CTCF insulators flank repetitive elements in the genome 
(Cho et al., 2005).  
 Three-dimensional organization of the genome  
Linear DNA is condensed ~100,000-fold by packaging with histones, forming nucleosomes into 
chromatin. At the interphase, de-condensed chromosomes occupy specific regions in the nucleus termed 
chromosome territories (Branco & Pombo, 2006). The positioning of the genes within the nucleus, in 
relation to other genes or nuclear structures, is important and is able to modulate gene function. The genome 
can further spatially segregate into distinct transcriptionally active (A-type) or inactive (B-type) regions 
termed compartments, harboring chromatin of similar states (Chen & Lei, 2019). High-throughput 
chromosome conformation capture (Hi-3C) methods allowed to show that the genome can be subdivided 
into approximately 2,000 topologically associated domain (TADs), the sub megabase region with strong 
contacts within each TAD, but limited contacts between different TADs. Higher resolution chromosome 
conformation capture carbon copy (5C) methods allowed to resolve sub-TADs within the TADs (Ghirlando 
& Felsenfeld, 2016). Inherent to TAD organization are chromatin loop that form between distant loci within 
the TAD or between sequences at TAD boundaries (Chen & Lei, 2019).  
The three-dimensional organization of the genome (Figure 1.3) is the result of the interplay 
between the transcriptional state of genes and the activity of architectural proteins, such as cohesin, YY1 
and CTCF (Arzate-Mejía et al., 2018). CTCF was described as a universal “master weaver” of genome in 
all multicellular organisms, which may be important for the organization and regulation of genomic 
functions in three dimensions, together with cohesin, including the formation of TADs, long-range DNA 
interactions, delimiting TAD borders and the formation loops between two CTCF sites in opposite or 
convergent orientation (Braccioli & de Wit, 2019; Phillips & Corces, 2009).  
CTCF is involved in chromatin interactions between and within chromosomes across the genome. 
CTCF loops can contain active chromatin separated from inactive chromatin outside the loops and vice 
versa (Holwerda & de Laat, 2013). One of the main roles of CTCF in loop formation may be to facilitate 
the interaction between regulatory sequences and promoters during transcription initiation, as it has been 
proven for MYC gene (Hyle et al., 2019). Most CTCF-mediated interactions are local and involve loci less 
than 1 Mb apart (Ghirlando & Felsenfeld, 2016). Sequences adjacent to loop anchors are enriched in active 
histone modifications, RNA polymerase II (RNAPII), housekeeping genes and TSSs, suggesting that CTCF 
chromatin loops could represent topological structures within which transcription can take place (Arzate-
Mejía et al., 2018). Nevertheless, chromatin looping requires, not only CTCF binding to cohesin, but also 
to non-coding RNAs (ncRNAs), which are implicated in curving the domain borders and in the formation 
of large regions of repressive or active chromatin (Yamamoto & Saitoh, 2019).  
In mammals, most long-range interactions preferentially occur between convergently oriented 
CTCF binding sites, in a head-to-head configuration (Chen & Lei, 2019). Reversal of orientation of paired 
CTCF sites leads to disruption of looping and formation of a new loop (Ghirlando & Felsenfeld, 2016). 
Cohesin and CTCF form chromatin loops according to the currently favored loop extrusion model. The 
loop is first stabilized by a pair of cohesin molecules that acts as the extrusion complex and they enlarge 
the loop as they move away, either carrying along CTCF molecules with them until oriented binding sites 
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are reached or stopping when properly oriented bound CTCFs are encountered. This process stops once the 
cohesin complex encounters CTCF-bound sites in a convergent orientation (Arzate-Mejía et al., 2018). 
Cohesin’s DNA release factor WAPL is essential in limiting loop length by releasing cohesin from the 
DNA, avoiding the formation of abnormally enlarged loops (Braccioli & de Wit, 2019).  
 
Figure 1.3. Three-dimensional genome organization. Chromosomes are organized into compartments followed by 
topologically associated domains (TADs) and loops. CTCF and cohesin are involved in chromatin loop formation and 
30% of the loops bring together promoters and enhancers. Adapted from Wang et al., 2019. 
Insulator proteins often occupy TAD boundaries and CTCF binding sites are enriched in 20 kb 
windows surrounding the boundaries of TADs (Holwerda & de Laat, 2013; Chen & Lei, 2019). Interruption 
CTCF or cohesin binding may damage TAD boundary, leading to different interactions and genes located 
in the affected domains can become deregulated (Gröschel et al., 2014; Liu et al., 2019). For example, an 
inversion on chromosome 3 in acute myeloid leukemia (AML) disrupts TAD boundaries, resulting in the 
formation of new hybrid TADs containing parts of each flanking genomic region. As a result, an enhancer 
that normally regulates the GATA2 gene is repositioned within the TAD that contains the EVI oncogene 
(Gröschel et al., 2014).  
1.5. CTCF IN DEVELOPMENT AND CANCER 
CTCF is involved in many aspects of human development, including very early, postnatal and 
adult development. The effect on CTCF on cell physiology is highly dependent on the developmental stage 
and on the chromatin organization of its target genes (Arzate-Mejía et al., 2018). CTCF appears to play a 
role in the change of intra- and interdomain interactions that modulates gene expression during the 
development (Holwerda & de Laat, 2013). Additionally, CTCF is a regulator of mRNA alternative splicing, 
which also plays an important role in cellular differentiation and development (Braccioli & de Wit, 2019). 
CTCF is important for neuronal development (Arzate-Mejía et al., 2018) and it has been reported that 
frameshift mutations in the CTCF gene can cause intellectual disabilities, such as autosomal dominant 
mental retardation 21 (Gregor et al., 2013). Other disorders that affect human growth, such as Beckwith-
Wiedemann and Silver-Russell syndromes, characterized by alterations in the IGF2-H19 ICR, are closely 
linked to CTCF insulator function (Herold et al., 2012).  
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As mentioned above, CTCF levels markedly impact cellular functions, and the alteration of CTCF 
functions is related with many diseases, not only developmental disorders, but it is also dysregulated in 
cancer. CTCF gene is frequently deleted in several human malignancies (Filippova et al., 1998). Therefore, 
and given the essential role of CTCF, it has been proposed as a candidate tumor suppressor gene, whose 
expression is essential for cell viability and protection against cancer (Bailey et al., 2018).  
In order to elucidate the cause that might disrupt CTCF activity in human tumors, both CTCF ZF 
mutations and CTCF binding sites mutations have been widely studied (Debaugny & Skok, 2020). On one 
hand, mutations of the ZFs of CTCF were detected in several cancers, such as endometrial cancer (ZFs 4-
5 spacer region R377C mutation), prostate cancer (ZF3 H345R mutation), Wilms´ tumor (ZF3 R339W and 
ZF7 R448Q mutations) and breast cancer (ZF3 K344E mutation) (Filippova et al., 2002; Oh et al., 2017). 
Heterozygous deletion or mutations of CTCF, together with cohesin and other epigenetic modulators 
mutations, were observed in Down syndrome–related leukemia (Yoshida et al., 2013). On the other hand, 
mutations in the CTSs, mainly AT>GC and AT>GC substitutions, can disrupt the binding of CTCF and 
cohesin and are frequent in some types of cancer (Katainen et al., 2015), such as T-cell acute lymphoblastic 
leukemia (T-ALL) (Hnisz et al., 2016), liver cancer (Fujimoto et al., 2016) and gastrointestinal cancers 
(Guo et al., 2018).  
Regarding with the epigenetics of cancer, abnormal CTCF binding due to aberrantly methylated 
CTCF binding sites has also been reported in various cancers, including testicular cancer, colorectal cancer, 
bladder cancer and ovarian cancer (Oh et al., 2017). Dysregulation of CTCF binding events in cancer is not 
always associated with changes in DNA methylation or mutations in CTCF binding sites, but can also be 
associated with altered chromatin interactions mediated by CTCF and cohesin. Specific alterations in CTCF 
occupancy, including both gained and lost sites, have been documented across different types of cancers, 
such as T-ALL, AML, breast cancer, colorectal cancer, lung cancer and prostate cancer (Fang et al., 2020).  
The cBioPortal for Cancer Genomics platform (http://www.cbioportal.org) contains several 
studies of cancer genomics performed by The Cancer Genome Atlas (TCGA) and other groups. Due to the 
role of CTCF in cancer, mutations of CTCF and its partners have been analyzed, including amplifications, 
deletions, and copy number alterations. Interestingly, leukemia has not been profiled for CTCF mutations 
in the cBioPortal analysis performed by other authors (Debaugny & Skok, 2020; Voutsadakis, 2018). 
1.6. ERYTHROID DIFFERENTIATION AND MODELS 
Mammalian hematopoiesis produces approximately 10 distinct cell types, the most abundant of 
which belongs to the erythroid lineage (Barminko et al., 2015). An adult human produces approximately 
2.5 x 1011 red blood cells (RBCs) and 1 x 109 white blood cells per day in the bone marrow that are released 
into the peripheral blood, in order to replenish the cells that are taken out of the circulation by macrophages 
120 days after (Valent et al., 2018). Maintenance of this rapid turnover requires efficient erythropoiesis 
through proliferation and differentiation of hematopoietic stem cells (HSCs) (Tumburu & Thein, 2017).  
HSCs can reconstitute the entire blood system of an adult and sustain the lifelong production of 
all blood lineages (Pater & Dzierzak, 2015). In mammals, the sequential sites of hematopoiesis include the 
yolk sac, the aorta-gonad mesonephros region, the placenta, the fetal liver and finally the bone marrow 
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(Orkin & Zon, 2008). Positive selection for human HSCs relies on expression of CD34, c-Kit or stem cell 
factor (SCF) receptor, IL-6R, Thy-1 and CD45RA markers (Pater & Dzierzak, 2015), but CD34 is 
considered the most inclusive marker for HSCs (Huang et al., 2011). HSCs have the ability to self-renew 
through asymmetric cell divisions and its perturbation results in leukemia (Pater & Dzierzak, 2015). In fact, 
chronic myeloid leukemia (CML) arises from a multipotent HSC containing a reciprocal translocation 
between chromosomes 9 and 22 (Philadelphia chromosome), encoding the BCR-ABL chimeric protein 
with constitutively active tyrosine kinase (Yang et al., 2015).  
RBCs are generated from HSCs through the process of differentiation known as erythropoiesis 
(Figure 1.4). The earliest restricted erythroid progenitors arise from megakaryocyte erythroid progenitors 
(MEPs) that form burst-forming unit erythroid (BFU-Es), which respond to erythropoietin (Epo), SCF, 
IGF1, corticosteroids, IL3 and IL6. BFU-Es give rise to colony-forming unit erythroid (CFU-Es) that are 
committed to terminal erythroid differentiation and depend on Epo for survival. The earliest 
morphologically identifiable erythroid precursor is the proerythroblast (ProE), that differentiates into 
basophilic erythroblast, polychromatophilic erythroblast, orthochromatic erythroblast, and reticulocyte 
(Figure 1.4). With each division, the erythroblast becomes progressively smaller, its nucleus condenses 
to be finally extruded, organelles are lost via autophagy and hemoglobin (Hb) accumulates in the cytoplasm 
(Barminko et al., 2015; Nandakumar et al., 2016). Erythroid terminal differentiation requires proliferation 
arrest and exit from the cell cycle, with a balance between proliferation and maturation (Yang et al., 2017).  
 
Figure 1.4. Erythroid cell differentiation. Differentiation from HSC to erythrocyte involves different progenitors 
characterized by different morphology, that express different surface markers, respond differently to Epo and SCF, 
among other growth factors, exhibit an increase in hemoglobin synthesis and are regulated by many transcription 
factors in a different way, including the TFs studied in this work.  
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Erythropoiesis in healthy individuals involves balanced high levels of transcription of α- and β- 
like globin genes and mutations in those genes or their regulatory regions lead to disease (Mahajan et al., 
2009). A variety of β-like globin molecules are produced because the human β-globin locus is 
developmentally regulated (Sankaran & Orkin, 2013). Hemoglobin switching is the sequential change in 
globin gene expression during development (Barminko et al., 2015). Primitive erythroblasts (EryPs) mainly 
express the embryonic form of a β-like globin known as ε-globin (forming ζ2ε2 and α2ε2) (Demirci & 
Tisdale, 2018). Then, definitive erythroblasts (EryDs) mainly produce γ-globin, that in combination with 
adult α-globin chains into a stable tetramer forming fetal hemoglobin (HbF, α2γ2). Reticulocytes that enter 
the circulation become fully mature RBCs expressing adult hemoglobin (HbA, α2β2) through a 
transcriptional switch from γ- to β-globin (Sankaran & Orkin, 2013).  
CTCF bound chromatin positions surrounding the α-globin TAD serve to restrict and guide local 
enhancer interactions to α-globin promoters (Hanssen et al., 2017). Importantly, the insulator CTCF is 
removed of the α-globin locus and rearranged on other specific site facilitating the transcription of α-globin 
gene during erythroid development (Mahajan et al., 2009). The transcriptionally active β-like globin genes 
are closely positioned with the locus control region (LCR) in erythroid cells and form enhancer-promoter 
loops mediated by five CTCF/cohesin binding sites around the β-globin locus. Recruitment of CTCF and 
Rad21 to CTCF sites near the β-globin locus and loop formation are dependent on GATA1, TAL1 and 
KLF1 (Kang et al., 2017).  
The development and maturation of RBCs in the bone marrow is regulated by the supporting 
microenvironment, consisting of macrophages and stromal cells (Valent et al., 2018), and a complex genetic 
program involving a wide variety of molecules (Orkin & Zon, 2008; Pater & Dzierzak, 2015). The main 
regulator of RBC production is Epo, a glycoprotein hormone that activates intracellular signaling through 
binding to its receptor, EpoR. This stimulation upregulates the expression of globins, transferrin receptor 
and some membrane proteins that are characteristic of erythrocytes. Epo initiates expression of erythroid 
specific genes and protects against apoptosis (Perry & Soreq, 2002).  
The binding of Epo to its receptor activates the cytoplasmic tyrosine kinase Janus Kinase 2 
(JAK2), which triggers a downstream signaling cascade via the signal transducer and activator of 
transcription 5 (STAT5), phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
pathways to support the proliferation and differentiation of erythropoietic progenitors (Hanssen et al., 2017; 
Moore & von Lindern, 2018). STAT5, together with TAL1, GATA1 and KLF1, binds enhancers to direct 
erythroid differentiation (Hanssen et al., 2017) and induces the expression of BCL-XL to maintain viability 
during terminal maturation (Moore & von Lindern, 2018). SCF, as well as Epo, activates PI3K/PKB 
signaling, which activates mammalian target of rapamycin (mTOR), a critical factor in protein synthesis 
(Moore & von Lindern, 2018). Epo also modulates the erythroid epigenome through the alteration of 
histone mark signatures across several thousand enhancer locations during erythropoiesis (Hanssen et al., 
2017). The first phase of CFU-E erythroid differentiation is highly Epo-dependent, whereas later stages are 
no longer dependent on Epo and EpoRs are lost during terminal differentiation (Hattangadi et al., 2011). 
The most extensively used model organisms in the study of erythropoiesis are mice and zebrafish. 
The most important cellular model is the primary culture of HSCs (i.e., CD34+ cells) obtained from the 
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peripheral blood, BM, cord blood or fetal liver (Nandakumar et al., 2016). Erythroid differentiation can be 
induced in CD34+ cells from cord blood using Epo (Mahajan et al., 2009). The human erythroleukemia cell 
lines are very important too, including K562 cells, although they show neither an adult-type hemoglobin 
expression pattern, nor terminal differentiation (Nandakumar et al., 2016).  
K562, derived from CML, are multipotent cells that can be induced to differentiate into several 
hematopoietic pathways. More specifically, erythroid differentiation can be induced in K562 cells using 
the anti-metabolite cytosine arabinoside (Ara-C), one of the key drugs for the treatment of leukemia, that 
inhibits the initiation of replication and incorporates into DNA leading to the inhibition of DNA elongation 
(Delgado et al., 1995). High concentrations of Ara-C provoke apoptosis, but low concentrations induce 
erythroid differentiation (Yamada et al., 1998). Additionally, Imatinib is a BCR-ABL inhibitor that is 
currently being used to treat CML and in low concentration induces proliferation arrest by regulating RAS-
ERK cascade, and erythroid differentiation of CML cells (Gómez-Casares et al., 2013; Yang et al., 2015). 
Erythroid differentiation can be confirmed with an increase in hemoglobin accumulation and is 
accompanied by an increased inhibition of cell growth (Woessmann et al., 2004).  
CTCF is critical for hematopoiesis and the loss of CTCF results in hematopoiesis failure (Kim et 
al., 2017). Previous studies of our group in K562 cells showed that CTCF is differentially expressed and 
post-translationally modified depending on the differentiation pathway (Delgado et al., 1999). Additionally, 
CTCF overexpression has a stimulating effect on differentiation into the erythroid lineage, but not into the 
megakaryocytic lineage (Torrano et al., 2005). However, the mechanisms by which CTCF regulates the 
expression of several hematopoietic genes are still unknown. Previous unpublished results indicate that 
CTCF overexpression modulates the expression of certain genes encoding erythroid TFs, that will be the 
focus of this work. 
1.7. ERYTHROID TRANSCRIPTION FACTORS 
Erythropoiesis is tightly controlled by a combination of TFs that regulate erythroid-specific gene 
expression in a stage-specific and context-dependent manner, and their dysregulation is associated with 
chromosomal translocation and leukemias (Nandakumar et al., 2016; Perry & Soreq, 2002). The core 
erythroid network (CEN) (Figure 1.5) is necessary for proper RBC development, and it is comprised of 
DNA-binding TFs (GATA1 or its close relative GATA2, TAL1 and KLF1) and non-DNA-binding (LDB1 
and LMO2) (Nandakumar et al., 2016).  
 
Figure 1.5. Erythroid transcription factors regulate gene expression. The core erythroid network (CEN) is a 
pentameric complex formed by DNA-binding factors (TAL1/SCL, KLF1 and GATA1/2) and non-DNA binding 
transcription factors (LMO2 and LDB1). The CEN, together with other TFs from LDB1 complexes, such as E2A, regulates 
the expression of erythroid genes.  
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- GATA-binding factor 2 (GATA2) is a TF that, together with LMO2, is involved in HSC production, 
survival, self-renewal or function (Doré & Crispino, 2011; Orkin & Zon, 2008). GATA family 
transcription factors bind the DNA consensus sequence (A/T)GATA(A/G) through 2 ZFs. 
Commitment of HSCs to the erythroid lineage is associated with the “GATA switch”, which implicates 
GATA2 downregulation after the activation of GATA1, which is itself a GATA2 target gene (Love et 
al., 2014). As GATA1 protein levels increase, GATA1 replaces GATA2 at the β-globin locus and 
induces massive upregulation of hemoglobin gene expression (Doré & Crispino, 2011).  
- GATA-binding factor 1 (GATA1) is a ZF TF that was identified to bind important DNA regulatory 
sequences in globin genes (Tsai et al., 1989). GATA1 is mainly expressed in MEPs and erythroblasts 
and is required for the maturation of several blood lineages, including erythrocytes, megakaryocytes, 
eosinophils, and mast cells (Doré & Crispino, 2011; Love et al., 2014). GATA1 is one of the master 
regulators of erythropoiesis, inducing the expression of EpoR, commitment to the erythroid lineage 
and transcription of adult β-globin gene (HBB) (Moore & von Lindern, 2018; Valent et al., 2018). 
There are GATA-binding motifs in promoters and enhancers of erythroid genes, TFs and co-factors, 
such as LMO2 (Osada et al., 1995), TAL1 and KLF1 (Merika & Orkin, 1995). The transcription factor 
hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1) inhibits the expression of GATA1, 
maintaining an undifferentiated state of erythroid precursors (Elagib et al., 2004). 
- T-cell acute lymphocytic leukemia protein 1 (TAL1), also known as stem cell leukemia (SCL), is a 
basic helix-loop-helix TF that is detected in early hematopoietic progenitors and in more mature 
megakaryocytes, erythroid and mast cells. TAL1/SCL expression increases during erythroid 
differentiation and represses differentiation of myeloid progenitors (Doré & Crispino, 2011; Perry & 
Soreq, 2002). Despite the requirement for TAL1/SCL in HSC generation, it is not specifically required 
for HSC long-term repopulating due to functional redundancy with LYL1 (Love et al., 2014). 
TAL1/SCL binds E-box (CAGGTG) DNA elements and participates in a DNA-bound complex 
containing the transcription factors E12/E47, GATA1, LDB1 and LMO2. TAL1/SCL depletion results 
in the inhibition of blood formation because it regulates a broad network of hematopoietic transcription 
factors (Doré & Crispino, 2011; Perry & Soreq, 2002). 
- Krüppel-like factor 1 (KLF1), also known as Erythroid Krüppel-like factor (EKLF), is a ZF TF 
encoded by the KLF1 gene and it is essential for the final steps of definitive erythropoiesis, promoting 
the maturation of erythroblasts to erythrocytes (Orkin & Zon, 2008). KLF1 regulates approximately 
700 erythroid genes, primarily as a transcriptional activator, and promotes chromatin loop formation 
(Tumburu & Thein, 2017). In erythroid cells, KLF1 gene is a direct target of GATA1 (Orkin & Zon, 
2008). KLF1, as well as GATA1, is involved in bipotential decisions of the MEPs, inhibiting the 
megakaryocyte development and promoting erythroid lineage development (Siatecka & Bieker, 2011). 
More specifically, KLF1 represses the megakaryocytic factor Friend leukemia integration 1 (FLI1) 
(Doré & Crispino, 2011). KLF1 binds to the DNA consensus sequence 5´-NCNCNCCCN-3´, located 
in HBB promoter and recruits a chromatin remodeling complex for the transcription of the HBB gene 
(Orkin & Zon, 2008). In mature erythroid cells, KLF1 regulates heme synthesis, membrane stability 
and iron procurement pathway (Doré & Crispino, 2011).  
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- LIM Domain Binding 1 (LDB1) is a transcription co-factor that is essential for chromatin loop 
formation and long-range interaction of the β-globin LCR enhancer with β-globin genes, which is 
required for their activation (Doré & Crispino, 2011). LDB1 is necessary for both primitive and 
definitive erythropoiesis (Love et al., 2014). LDB1 is a critical downstream effector of the 
transcriptional activation network of GATA1 (Doré & Crispino, 2011). LDB1 interacts with CTCF, 
which is important for enhancer looping in erythroid cells. In erythroid cells, many enhancers of 
erythroid genes are bound by LDB1. LDB1 complex may specify the enhancers to be involved in 
looping, as LDB1-bound enhancers loop to genes that are occupied by CTCF (Lee et al., 2017). 
- LIM domain-only protein 2 (LMO2) co-factor, encoded by LMO2, contains two cysteine-rich LIM 
domains and is essential for the development of hematopoietic system (Orkin & Zon, 2008). Aberrant 
expression of LMO2 results in the development of T-cell related disease, including T-ALL (Cantor & 
Orkin, 2002). LMO2 does not bind DNA by itself but acts as a bridge between DNA-binding 
transcription factors such as SCL and GATA1 (Perry & Soreq, 2002). In erythroid cells, LMO2 forms 
a complex with the transcriptional regulators TAL1, E2A, LDB1 and GATA1 (Bhattacharya et al., 
2012; Brandt & Koury, 2009). Transcriptional regulation of LMO2 in erythroid cells appears to involve 
multiple distal regulatory elements (DRE) (90, 75, 40 and 12) upstream of LMO2 which overlap TFs 
(KLF1, GATA1, TAL1, LDB1) and CTCF/cohesin binding regions (Bhattacharya et al., 2012). 
The interaction between erythroid transcription factors and their DNA targets is summarized here 
below. SCL/TAL1 and its heterodimeric partner transcription factor E2A (also known as TCF3) recognizes 
a consensus E-box DNA sequence and GATA1 binds a GATA element located about 9-11bp away, which 
forms a paired E-box-GATA DNA motif. LMO2 and its partner LDB1 acts to bridge a SCL/TAL1-E2A 
and GATA1, forming the called LDB1 complexes. LDB1 complexes that contain GATA2, instead of 
GATA1 regulate a transcriptional program required for the generation and maintenance of HSCs. 
Substitution of GATA1 for GATA2 within the LDB1 complexes results in the induction of KLF1 and 
global erythroid gene activation (Cantor & Orkin, 2002; Love et al., 2014). LDB1 complexes and KLF1 
have independent binding sites in the genome, but frequently colocalize in many erythroid lineage–specific 
promoters (Li et al., 2013). KLF1 gene is a target of LDB1 complexes. GATA1 regulates the expression of 
KLF1, by binding to a paired E-box-GATA motif within the KLF1 promoter. GATA1, TAL1 and KLF1 
form an erythroid transcriptional network co-occupying >300 genes and are required for the expression of 
erythroid genes, including β-globin (HBB), and α-globin (HBA) (Love et al., 2014) (Figure 1.5). 
Other chromatin-associated proteins are also involved in this process. For instance, KLF1 recruits 
BRG1, a critical component of the Swi/Snf ATP-dependent chromatin remodeling complex. Another 
erythroid factor, Nuclear factor erythroid 2 (NFE2) associates with the MLL2 complex, which is 
responsible for H3K4 histone methylation (Orkin & Zon, 2008). Globin gene transcription is increased only 
after the binding of NFE2, TFIIB and Pol II (Hattangadi et al., 2011). Although LDB1 complexes function 
mainly as transcriptional activators, repressive potential can be conferred by recruitment of additional 
factors, such as nucleosome remodeling and deacetylase (NuRD) or PU.1 inhibitor (Love et al., 2014).  
Other TFs that play an important role in erythropoiesis are: 
- ETS1 belongs to the Erythroblast Transformation Specific (ETS) family of TFs and contains a winged 
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helix-turn-helix DNA binding domain that recognizes purine-rich DNA sequences containing a 
GGA(A/T) core. ETS1 stimulates the megakaryocytic differentiation pathway, while its 
downregulation is required for terminal erythroid maturation. ETS1 expression is detectable from 
HSCs to basophilic erythroblasts, and undetectable in successive stages. GATA2 promoter is a direct 
target of ETS1, with two ETS binding sites (Garrett-Sinha, 2013; Lulli et al., 2006).  
- MYB (myeloblastosis) is a TF encoded by MYB proto-oncogene that controls stem and progenitor cells 
of all hematopoietic lineages and lack of MYB is lethal (Stadhouders et al., 2012). MYB is abundantly 
expressed in immature hematopoietic cells of erythroid, myeloid, and lymphoid lineages, but needs to 
be downregulated to allow terminal differentiation (Perry & Soreq, 2002). MYB regulates several 
genes involved in cell-cycle and proliferation (MYC), erythroid transcription factors (KLF1 and 
LMO2), globin genes, erythroid cytoskeleton proteins and surface proteins and antigens associated 
with erythroid differentiation (Hattangadi et al., 2011; Tumburu & Thein, 2017). There are five LDB1 
complex binding sites in the MYB-HBS11 intergenic region, consistent with active transcription of both 
MYB and HBS11 genes. The interaction between the -36 and -81 kb sites upstream MYB and the CTCF 
binding site in the intron 1 of MYB locus is required for MYB expression (Stadhouders et al., 2012).  
- MYC is a TF encoded by MYC protooncogene and is required for the balance between self-renewal 
and differentiation of HSCs. Different lineages of hematopoietic cells differ in their requirement for 
MYC to regulate their proliferation and differentiation. In K562 cells, MYC impairs Ara-C induced 
erythroid differentiation, but not megakaryocytic differentiation. MYC impairs the upregulation of 
many erythroid-specific genes, as well as that of TFs that determine erythroid differentiation (Delgado 
& León, 2010). 
2. HYPOTHESIS AND OBJECTIVES 
As it has been previously explained, CTCF may play a key role in the regulation of erythroid 
differentiation. Among hematopoiesis, overexpression of CTCF promotes erythroid cell differentiation of 
human myeloid leukemia cells (Torrano et al., 2005). Additionally, microarray assays performed in our 
group have identified several erythroid genes that are regulated by CTCF, including transcription factors 
genes with an important role in erythroid differentiation (unpublished data). However, the underlying 
molecular events of these effects remain unknown. We hypothesized that CTCF could bind to and regulate 
the expression of specific erythroid transcription factor genes.  
The general aim of this work is to gain further insight into CTCF function in the regulation of 
erythroid cell differentiation in human hematopoietic cells. For this purpose, we stablished the following 
aims: 
1. Analyze the effects of CTCF downregulation on erythroid cell differentiation in K562 cell line 
and CD34+ primary progenitor cells. 
2. Analyze the effects of CTCF downregulation in the expression of previously identified erythroid 
transcription factors, at both mRNA and protein levels. 
3. Analyze CTCF binding sites to the erythroid transcription factor genes, and the possible chromatin 
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interactions, as well as the histone marks, in different human cell lines using the ENCODE project. 
4. Search for possible correlations between CTCF expression or mutations or CTCF binding site 
mutations and erythroid transcription factors expression or mutations in hematological cancers 
using cBioPortal. 
3. MATERIALS AND METHODS 
3.1. CELL CULTURE 
 Cell lines 
Three human cell lines were used in this work: K562 (ATCC), HEK-293T (Laboratory collection) 
and HeLa (ATCC). K562 cell line is derived from human CML. K562 cells have the capability of 
differentiating along the erythroid lineage and they grow in suspension. 293T cell line is a highly 
transfectable derivative of human embryonic kidney 293 cells and they grow adhered to the plate. HeLa 
cell line is derived from human cervical cancer and it is also an adherent cell line. All cell lines were grown 
in basal media (RPMI (Roswell Park Memorial Institute) medium for suspension cell culture and DMEM 
(Dulbecco's Modified Eagle Medium) for adherent cell culture; GibcoTM) supplemented with 10% fetal 
bovine serum (FBS, GibcoTM), 150 µg/ml gentamycin and 2 µg/ml ciprofloxacin. All cell lines were 
maintained at 37 ºC in a humidified 5% CO2 atmosphere.  
 Purification and culture of human CD34+ cells 
In order to carry out the experiments with HSCs, primary human CD34+ cells were isolated from 
human umbilical cord blood (Banco de Sangre y Tejidos de Cantabria). First, 15 ml of fresh blood were 
diluted with phosphate-buffer saline (PBS) supplemented with 2 mM ethylenediaminetetraacetic acid 
(EDTA) and 100 U/ml DNase in a final volume of 40 ml. Then, 20 ml of diluted blood were carefully added 
to centrifuge tubes containing 8.6 ml of Ficoll-Paque PlusTM (GE Healthcare), avoiding the disruption of 
Ficoll layer. Tubes were centrifuged at 400 g for 35 min at 20 ºC without brake. The upper layer containing 
plasma and platelets was removed, and the mononuclear cell layer was transferred to a clean tube and 
washed two times with PBS-2 mM EDTA. Mononuclear cells were counted and resuspended in freezing 
medium (90% FBS and 10% dimethyl sulfoxide (DMSO) as cryoprotectant) to freeze at -80 ºC until the 
purification of CD34+ cells. 
The purification of CD34+ cells was performed with a magnetic beads separation kit (CD34 
MicroBead Kit Ultrapure and MACS Columns, Miltenyi Biotec). Mononuclear cells were centrifuged, and 
the cellular pellet was resuspended in RPMI medium and filtered with a column. It was centrifuged 5 min 
at 1200 rpm and the pellet was resuspended in a final volume of 300 µl of buffer PBS-2mM EDTA-0.5% 
bovine serum albumin (BSA) per 108 cells. To carry out the magnetic labelling, blocking reagent (100 µl) 
and CD34+ beads (100 µl) were added to the cell suspension and it was maintained 30 min at 4 ºC with 
rotation. The beads were washed with buffer PBS-2mM EDTA-0.5%BSA and centrifuged 10 min at 300 
g. The pellet was resuspended in 500 µl of buffer and filtered with a MACS column in the presence of a 
magnetic field. The column was washed 3 times to remove unlabeled cells. Then, the column was separated 
from the magnet and placed on a collection tube. The CD34+ cells were eluted with buffer PBS-2mM 
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EDTA-0.5%BSA by firmly pushing the plunger into the column. Finally, the cells were counted, 
centrifuged, and cultured in pre-stimulation medium. 
 Induction and assessment of erythroid cell differentiation 
Exponentially growing K562 cells (2.5 x 105 cell/ml) were treated with 1 µM 1-β-D-
arabinofuranosylcytosine (Ara-C, Sigma-Aldrich) or 0.5 µM Imatinib (LC Laboratories) up to 3 days to 
induce erythroid cell differentiation (Cañelles et al., 1997; García-Gaipo, 2019). Imatinib has emerged as 
the lead compound to treat the chronic phase of CML (O’Brien et al., 2003) targeting the BCR-ABL 
oncogene that causes CML in humans, so it is an inhibitor of its oncogenic tyrosine kinase (Jacquel et al., 
2007; Roskoski, 2003). Besides triggering apoptosis in K562 cells, Imatinib also mediates their erythroid 
differentiation (Jacquel et al., 2007). Ara-C is also being widely used in the treatment of acute and chronic 
leukemias, since it is a cytosine analogue that inhibits DNA polymerases α, δ, and ε, and RNA polymerases 
resulting in the inhibition of DNA synthesis and repair (Reiter et al., 2001). 
On the other hand, expanded CD34+ cells were cultured in StemSpan™ Erythroid Expansion 
Supplement (100X), containing SCF, IL-3 and Epo up to 5 days to selectively promote the expansion and 
differentiation of erythroid progenitor cells from CD34+ cells. Epo is the primary regulator of erythropoiesis 
and it has been widely used to induce erythroid differentiation of human CD34+ cells in culture (García 
Gaipo, 2019; Kumkhaek et al., 2013; Mahajan et al., 2009). 
Cells were collected at day 0 as negative control and the following 3 days after the induction of 
the erythroid differentiation. Erythroid differentiation was assessed by the expression of some specific 
erythroid markers, such as the production of hemoglobin, as well as by the benzidine test. Benzidine test is 
based on the catalytic reaction between a solution of benzidine (1,1'-biphenyl-4,4'-diamine) in acetic acid 
and hemoglobin in presence of hydrogen peroxide (H2O2). It has been widely used in clinics for the 
detection of blood in the urine because hemoglobin-containing cells turn into blue (Ali et al., 2019; Ingham, 
1932; Viola et al., 2008). To perform this test, a mixture of benzidine:H2O2 (50:1 v/v) was prepared and 20 
µl were added to 5 x 104cells in 20 µl of R10F. Catalytic reaction occurred on ice and, after 10 min of 
incubation, 5 images of each conditions were obtained with the microscope. A minimum of 200 cells were 
counted with the ImageJ software. The percentage of benzidine-positive cells was obtained from the 
quotient between the number of hemoglobin-producing cells (blue) and the number of non-hemoglobin-
producing cells (white).  
 Cell proliferation assay 
Exponentially growing cells were counted using the NucleoCounter® NC-100™ (ChemoMetec), 
a high precision automated cell counter that counts suspension cells based on the staining of DNA. First, a 
volume of cell suspension was mixed with an equal volume of lysis buffer (Reagent A100) to disrupt plasma 
membranes and an equal volume of stabilizing buffer (Reagent B) to stabilize the cell nuclei and avoid 
DNA degradation. Then, the diluted sample was introduced in the NucleoCassette™ containing 
immobilized propidium iodide that stains the nuclei and the system displayed total cell number. Considering 
the dilution of the sample, the cellular concentration was obtained to plot the proliferation curve.  
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3.2. LENTIVIRAL INFECTION 
 Plasmid DNA purification  
Plasmid DNA for transfections was extracted from plasmid-containing bacteria and subsequently 
purified using the Plasmid Midi Kit (Qiagen). The plasmids used in this work are shown in Table 3.1 and 
their elements are shown in Figure 3.1. Both plasmids are provided with the bacterial and eukaryotic 
promoter (human phosphoglycerate kinase (hPGK) in pLKO and doxycycline-inducible promoter in the 
case of pTRIPTZ), an origin of replication (pUC) for double stranded replication, f1 origin of replication 
to enable single stranded replication and packaging into phage particles, puromycin resistance gene for 
mammalian selection, antibiotic resistance for bacterial selection (ampicillin or hygromycin), 3′ self-
inactivating long terminal repeat (SIN/3′ LTR) for increased lentivirus safety, 5′ long terminal repeat (5′ 
LTR), and RNA packaging signal (Psi). 
Table 3.1. Plasmids used in this work and their origin.  
PLASMID CONSTRUCT ORIGIN 
pLKO control Lentiviral empty vector. Sigma-Mission® 
pLKO shCTCF Lentiviral shRNA for human CTCF gene. Sigma-Mission® 
pTRIPTZ control TRIPTZ lentiviral empty vector. DharmaconTM GE 
Healthcare 
pTRIPTZ shCTCF TRIPTZ lentiviral shRNA for human CTCF gene, 
inducible by tetracyclines.  
DharmaconTM GE 
Healthcare 
pCMV-VSV-G VSV-G gene encoding envelope protein for producing 
lentiviral particles. 
Addgene 
psPAX2 GAG and POL genes encoding packaging lentiviral 
proteins. 
Addgene 
 
Figure 3.1. Maps of the vectors used in this work. Elements of a) lentiviral plasmid vector pLKO.1-puro and b) pTRIPZ 
inducible lentiviral shRNA vector. Adapted from Addgene. 
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Plasmid-containing bacteria were grown by streaking from a glycerol stock in LB-agar plate with 
ampicillin, which was incubated overnight at 37 ºC. A single colony was inoculated into 10 ml LB growth 
medium containing antibiotic (100 µg/ml ampicillin) and incubated for 6 h in an orbital shaking incubator 
at 37 ºC and 160 rpm. After incubation, the culture was added to 200 ml LB growth medium containing the 
same selection antibiotic and grown overnight in the same conditions. The following day, bacterial culture 
was centrifuged at 6000 rpm for 10 min at 4 ºC and plasmid DNA was purified following manufacturer´s 
instructions.  
As a summary, for plasmid DNA extraction the cellular pellet was resuspended in a buffer with 
RNase to degrade RNA, then it was lysed with detergent at alkaline pH (SDS and NaOH) to break the 
plasma membrane and denaturalize proteins, chromosomal DNA and plasmid DNA. The pH was 
neutralized with potassium acetate, making the proteins and chromosomal DNA to precipitate, while the 
plasmid DNA remains in solution. The plasmid DNA was filtered and washed with an equilibrated column 
and then it was eluted with NaCl-Tris-HCl-isopropanol. It was centrifuged, the DNA pellet was washed 
with ethanol, and finally resuspended in MilliQ water. Plasmid DNA concentration was determined by 
measuring A260nm using a microvolume spectrophotometer (Thermo ScientificTM NanoDrop 2000).  
 Lentivirus production 
Lentiviral particles were produced to transduce different cell lines in order to downregulate CTCF 
expression. Lentivirus were produced in HEK293T transfected with the plasmid DNA using the 
Polyethylenimine (PEI) cationic lipids-based method. HEK293T were transfected with 3 distinct plasmids: 
• pCMV-VSV-G: plasmid containing VSV-G gene encoding envelope protein. 
• psPAX2: plasmid containing GAG and POL genes from human immunodeficiency virus (HIV) 
encoding packaging proteins. 
• The plasmid of interest (pLKO EV, pLKO shCTCF, pTRIPTZ EV or pTRIPTZ shCTCF) containing 
the short hairpin RNA (shRNA) for gene knockdown and other elements mentioned before, necessary 
to produce lentiviral particles.  
Cells were seeded in 150 mm plates at 70-80% of confluence and the complete medium D10F was 
changed to 13 ml of serum-free DMEM. The plasmids were mixed in the ratio 1:3:4 (pCMV-VSV-
G:psPAX2:plasmid of interest), this means 6:19:25 µg for 50 µg of total DNA. 100 µg PEI (Polysciences, 
Inc.) and 1 ml of serum-free DMEM were added to the mixture and incubated 10 min at RT. The final 
mixture of DNA, PEI and DMEM was added to the cells and, after 10 hours, the medium was replaced by 
15 ml of complete medium D10F. 48 hours after the transfection, the supernatant containing lentivirus was 
collected and stored at 4 ºC and 15 ml of complete medium were added. 72 hours after the transfection, the 
supernatant was collected and mixed with the previous one to be centrifuged 10 min at 1500 rpm. The 
supernatant was filtered through a 0.45 µm pore size sterile syringe filter (Merck Millipore) and the eluate 
was collected in a clean tube. 15% Polyethylene Glycol (PEG8000 40% in PBS) (Sigma-Aldrich) was 
added to make the lentiviral particles precipitate and they were stored at 4 ºC between 6 hours and one 
week. Finally, it was centrifuged for 30 min at 1500 rpm in order to concentrate the lentiviral particles, the 
pellet was resuspended in 150 µl serum-free medium and aliquots of 50 µl were stored at -80 ºC.  
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 Lentivirus tittering 
Lentiviral particles carrying antibiotic selection were tittered in HeLa cells grown in a 
concentration of 2 x 104cell/well in a 6-well plate in 1.5 ml of D10F medium. The medium was replaced 
by 1.5 ml of serum-free DMEM and incompletely adhered cells were infected with different concentrations 
of lentivirus (0.1, 0.5, 1 and 5 µl), in the presence of 5 µg/ml Polybrene (Sigma-Aldrich). 12 hours after the 
infection, 1.5 ml of complete medium D10F was added to the plates. 48 hours after the infection, the 
complete medium was refreshed and the selective antibiotic (500 µg/ml puromycin, Sigma-Aldrich) was 
added to the plates to select the infected cells, except for the negative control. Puromycin selection was 
maintained until control cells died (approximately, 3 days) and in the infected cells there were countable 
colonies. Then, the medium was removed, and the wells were washed twice with PBS. Cell colonies were 
stained with Crystal Violet solution (1% crystal violet dye in methanol) for 15 min. The dye was washed, 
and the number of colonies was counted under the microscope. Assuming that each colony was infected by 
one lentiviral particle, the lentivirus tittering (in colony forming units (C.F.U.)/ml) was calculated as the 
quotient between the number of colonies and the volume of virus that was added to the counted well. 
 Cell transduction  
K562 cells were seeded in a concentration of 2.5 x 105 cell/ml in 10 ml of serum-free RPMI 
medium. Cells were transduced with a multiplicity of infection (MOI) of 2 virus particle/cell and 5 µg/ml 
Polybrene was added to facilitate the infection. Cells were infected with pLKO EV and pLKO shCTCF 
lentiviral particles, produced as explained before. Cells were grown at 37 ºC o/n and, 12 hours after the 
infection, 10 ml of complete medium R10F were added to the cells. 48 hours after the infection, the medium 
was refreshed and 25 ml of D10F were added. Additionally, 1 µg/ml puromycin was added to select the 
infected cell population and the cells were grown 48 hours with the selective antibiotic at 37 ºC. At that 
point, erythroid differentiation was induced in transfected K562 cells with Ara-C or Imatinib in order to 
study the effect of CTCF downregulation in erythropoiesis. 
CD34+ cells were transduced with a MOI of 2 virus particle/cell. After 4 days growing, 
5 x 105cells were infected with 106 viral particles. For this purpose, plates were treated with 20 µg/µl 
retronectin for 2 h at room temperature (RT). Then, the plates were washed with an equal volume of PBS-
2%BSA for 30 min at RT. When the plates were ready to be used, the inducible viral particles pTRIPRZ 
EV and pTRIPTZ shCTCF were added for 5 h at 37 ºC. Finally, the viruses were removed, the cells were 
added to the plates in a concentration of 1 x 106 cell/ml with medium without cytokines and they were 
incubated at 37 ºC. The following day, an equal volume of StemSpanTM SFEM II medium supplemented 
with StemSpanTM CD34+ Expansion supplement 10X (StemCell Technologies) was added to the plates. 48 
hours after the infection, the selection with puromycin 0.5 µg/ml was performed. 72 or 96 h after the 
infection, 1 µg/ml doxycycline was added in one half of cells infected with each virus. Doxycycline induces 
the silencing of CTCF in the cells transfected with pTRIPTZ shCTCF but has no effect on the cells 
transfected with pTRIPTZ EV. The medium was refreshed and the selection with 0.5 µg/ml puromycin was 
maintained. 48 hours after the addition of doxycycline, one half of each condition was separated in two new 
conditions: with and without Epo, which induces erythroid differentiation. The selection with puromycin 
and the induction of shCTCF expression with doxycycline was refreshed.  
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3.3. RNA EXTRACTION AND GENE EXPRESSION QUANTIFICATION 
 RNA extraction and purification  
Total RNA was extracted and purified using TRIzolTM reagent (Invitrogen), which is a 
monophasic solution of phenol, guanidine isothiocyanate, and other components. It maintains the integrity 
of the RNA due to highly effective inhibition of RNase activity while disrupting cells. TRIzol™ Reagent 
is an improvement to the single-step RNA isolation method that was initially described with an acid 
guanidinium thiocyanate-phenol-chloroform mixture (Chomczynski & Sacchi, 1987). In the case of K562 
cells, between 2-10 x 106 cells were collected by centrifugation and the pellet was stored at -80 ºC until 
RNA extraction. For lysis and homogenization, 1 ml of Trizol reagent was added per sample. After 5 min 
of incubation at RT to permit complete dissociation of the nucleoproteins complex, 0.2 ml of chloroform 
per 1 ml of Trizol Reagent was added, mixed, incubated 2-3 min at RT and centrifuged for 15 min at 12000 
rpm and 4 ºC. The homogenate was separated into a colorless upper aqueous layer (containing RNA), an 
interphase, and a red lower organic layer (containing the DNA and proteins). The upper layer was collected 
in a new tube, mixed with 0.5 ml of isopropanol, incubated 10 min at RT and centrifuged for 20 min at 
12000 rpm at 4 ºC to precipitate RNA. The supernatant was discarded, and the RNA pellet was washed 
with 75% ethanol to remove impurities and centrifuged for 5 min at 7500 rpm and 4 ºC. The supernatant 
was discarded, and the pellet was dried at RT for 10 min. Then, the precipitated RNA was resuspended in 
25 µl of RNAse-free water for use in downstream applications. Finally, RNA concentration was determined 
by measuring A260nm using a microvolume spectrophotometer. Isolated RNA was stored at -80 ºC and can 
be further used in RT-PCR.  
 Reverse transcription and quantitative polymerase chain reaction (RT-qPCR)  
Gene expression was analyzed using quantitative real time polymerase chain reaction (RT-qPCR). 
For that purpose, complementary DNA (cDNA) was synthetized from RNA in a reverse transcription 
reaction, using the iScriptTM cDNA Synthesis Kit (Bio-Rad). First, 1 µg of RNA was mixed with nuclease-
free water in a total volume of 15 µl. Then, 4 µl of iScript Reaction Mix 5x were added, containing oligo(dT) 
and random hexamer primers. Finally, 1 µl of iScript Reverse Transcriptase was added. This enzyme is a 
modified Moloney murine leukemia virus reverse transcriptase that is preblended with RNase inhibitor. 
The complete reaction mix was incubated in a thermal cycler using the following protocol, according to 
manufacturer´s instructions: 5 min at 25 ºC (priming), 20 min at 46 ºC (reverse transcription) and 1 min at 
95 ºC (RT inactivation). The cDNA was more stable than RNA and was stored at -20 ºC until used.  
Quantitative PCR was performed to amplify the previously obtained cDNA using specific primers 
for gene of interest to quantify its expression, in terms of mRNA level. Primer sequences used in RT-qPCR 
assays are shown in Table 3.2. The mix for qPCR reaction was prepared mixing 11 µl of SyBR® Select 
Master Mix (Applied Biosystems), 8.7 µl of distilled water, 1.3 µl of specific primers (0.3 µM; stock 
concentration 100 mM in distilled water) and 1 µl of cDNA, for a final volume of 22 µl used for two 
duplicate wells. 10 µl of the mix were loaded in each well of a 96-well PCR plate. Reaction mix for each 
primer without cDNA was used as negative control to detect possible amplification from contaminating 
DNA or primer dimers. The qPCR reaction was performed in the CFX ConnectTM Real-Time PCR 
Detection System (Bio-Rad). The qPCR protocol for cDNA amplification was the following: 40 cycles of 
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10 min at 95 ºC (5 min at 95 ºC; 30 s at 55-60 ºC), 1 min at 95 ºC and 1 min at 55 ºC. The protocol for real 
time melting curve was 80 cycles of 10 s starting at 55 ºC and decreasing by half a degree each cycle.  
The CFX Connect Real-Time PCR Detection System was connected to a computer provided with 
the CFX ManagerTM software to analyze the data. Threshold cycles (Ct) were determined by default at the 
beginning of DNA amplification in the exponential phase. The Ct value is associated with the amount of 
amplified product in the reaction: the lower the Ct value, the more PCR product that is present because it 
takes fewer PCR cycles for that product to be detected over the background signal.  
The delta-delta Ct (2-ΔΔCt) method (Rao et al., 2013) was used in order to calculate the relative 
gene expression of our samples, normalized to mRNA expression of the ribosomal protein S14. First, the 
average of the Ct for the replicates was calculated for all the genes. Next, ΔCt was calculated for all the 
samples as the difference of the average Ct of the gene of interest and the average Ct of the housekeeping 
gene (S14) from the same sample: ΔCt = Gene Ct – housekeeping gene Ct. After that, the average ΔCt 
value for the control group was calculated. Then, the ΔΔCt was calculated for all the samples as the 
difference between the ΔCt of all samples and the average ΔCt of the control: ΔΔCt = sample ΔCt – average 
control ΔCt. After that, the 2-(ΔΔCt) was calculated, which represents the comparative fold gene expression 
values for all individual samples. Finally, the average 2-(ΔΔCt) and the standard deviation were calculated.  
Table 3.2. Primers used for RT-qPCR analysis. 
Amplified gene Primer sequences (5´→ 3´) Amplicon size 
CTCF Fw: TTA CAC GTG TCC ACG GCG TTC 365 bp 
Rv: GCT TGT ATG TGT CCC TGC TGG CA 
ETS1 Fw: TCC AGA CAG ACA CCT TGC AG 153 bp 
Rv: TGA GGC GAT CAC AAC TAT CG 
MYB Fw: AGC AAG GTG CAT GAT CGT C 157 bp 
Rv: GGG GGT GGA AGT TAA AGA AGG 
GATA2 Fw: CAA GAT GAA TGG GCA GAA CC 113 bp 
Rv: GCC ATA AGG TGG TGG TTG TC 
HEY1 Fw: GAC CGT GGA TCA CCT GAA A 123 bp 
Rv: ATT CCC GAA ATC CCA AAC TC 
LMO2 Fw: CTG AGC TGC GAC CTC TGT G 164 bp 
Rv: CGC ATT GTC ATC TCA TAG GC 
KLF1 Fw: CAG GTG TGA TAG CCG AGA CC 241 bp 
Rv: CCG TGT GTT TCC GGT AGT G 
NFE2L2 Fw: CGG TAT GCA ACA GGA CAT TG 246 bp 
Rv: AGA GGA TGC TGC TGA AGG AA 
MYC Fw: TCG GAT TCT CTG CTC TCC TC 157 bp 
Rv: CCT GCC TCT TTT CCA CAG AA 
TCF3 Fw: CAT CTG CAT CCT CCT TCT CC 
 
Rv: CCT CGT CCA GGT GGT CTT C 
Fw: forward primer; Rv: reverse primer.  
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3.4. PROTEIN EXTRACTION AND QUANTIFICATION  
 Cell lysis and protein extraction 
Protein levels were analyzed by Western blot. Between 2 to 10 x 106 K562 cells were collected 
by centrifugation and the pellet was stored at -80 ºC until protein extraction. For cell lysis, 50 ml of RIPA 
lysis buffer were prepared, containing: 1.5 ml NaCl 5M, 2.5 ml Tris pH 6.8, 0.25 g Sodium deoxycholate 
(NaDOC), 500 µl NP-40 (Igepal®) and 500 µl SDS. Protease inhibitor and phosphatase inhibitor were 
added to the RIPA lysis buffer immediately before using. Cell pellets were lysate in 200 µl of lysis buffer 
per 5 x 106 cells and samples were incubated for 15 min on ice. Then, samples were sonicated at 4 ºC using 
the Bioruptor® Plus sonication device (Diagenode) with high power mode for 10 cycles, each sonication 
cycle consisting of 30 s ON, 30 s OFF. After sonication, cell lysates were incubated on ice and centrifuged 
for 20 min at 14000 rpm and 4 ºC. The pellets were discarded and the supernatants, which contained the 
proteins, were placed on a new tube, and stored at -80 ºC until protein analysis by Western blot.  
 Western blot 
We performed Western blot to detect a specific protein from a sample and this technique consists 
basically in three steps: gel electrophoresis, blotting, and hybridization. Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) is used to separate proteins according to their molecular 
weights. We performed an initial Western blot with the same volume of all samples in order to equal the 
total protein concentration of our samples. The volume of each sample was mixed with distilled water and 
5X Laemli buffer for a final concentration 1X in a final volume between 20-25 µl. Then, the samples were 
heated for 5 min at 95 ºC and loaded in an SDS-PAGE gel, which acrylamide percentage depends on the 
molecular weight of the analyzed protein. 8% acrylamide gels were used to analyze the biggest proteins, 
15% acrylamide gels for the smallest proteins and percentages in between for intermediate proteins. As 
marker of known molecular weight, Precision PlusProteinTM Dual Colors Standars (Bio-Rad) was used.  
Vertical electrophoresis was performed at constant voltage of 175 V for 1 hour and a half, using 
electrophoresis running buffer TGS (25 mM Tris, 192 mM glycine and 0.1% SDS). When protein migrated 
until the end of the gel, electrophoresis had finished and proteins were transferred to a nitrocellulose 
membrane AmershamProtan Supported 0.45 NC (GE Healthcare Life Sciences), with 0.45 μm pore size, 
in a Mini-Trans Blot cell (Bio-Rad) using transfer buffer TG-MeOH (25 mM Tris, 192 mM glycine, and 
10% methanol). The transference was performed at constant amperage of 400 mA for 30 min to 1 hour, 
depending on the molecular weight of the protein of interest because the greater the time, the bigger the 
proteins that are transferred. In our conditions, we assumed 1 min per kDa, for proteins smaller than 60 
kDa. The transference was performed on ice to avoid the overheating.  
After the transference, the gel was stained with Coomassie Brilliant Blue solution (0.025% 
Coomassie Brilliant Blue R-250, 40% methanol and 10% acetic acid) for 10 min at RT with shaking and 
distained with water to check proteins load. To block unspecific binding sites, the membrane containing 
the proteins was incubated with TTBS (20 mM Tris-HCl pH 7.5, 150 mM NaCl and 0.05% Tween 20 in 
distilled-water) containing 10% non-fat dry milk for 1 h at RT. Then, the membrane was incubated with 
the primary antibody against the protein of interest (Table 3.3) overnight at 4 ºC or 4 h at RT in agitation.  
 
23 
 
Table 3.3. Primary antibodies used for Western blot. 
Primary antibody Molecular 
weight (kDa) 
Specie Dilution % BSA (in 
TTBS) 
Origin 
α-CTCF 130 Mouse 1:1000 1 Santa Cruz 
α-MYB 80 Rabbit 1:1000 5 Cell Signaling 
α-MYC 67 Rabbit 1:3000 5 Cell Signaling 
α-β-Tubulin 55 Mouse  1:1000 1 Santa Cruz 
α-GATA1 46 Rabbit 1:1000 1 Santa Cruz 
α-β-Actin 43 Mouse 1:3000 1 Santa Cruz 
α-HEY1 33 Mouse 1:1000 1 Santa Cruz 
α-LMO2 24 Mouse 1:1000 1 Santa Cruz 
α-γ-Hemoglobin 14 Mouse 1:1000 1 Santa Cruz 
 
After the incubation with primary antibody, the membrane was washed 3 times for 10 min with 
TTBS solution at RT with shaking. Then, the membrane was incubated with the corresponding fluorescent 
secondary antibody against the specie of primary antibody (Table 3.4) for 45 min at RT with shaking and 
in darkness. The membrane was washed three times for 10 min each with TTBS and the immunocomplexes 
were detected with the Odyssey® Infrared Imaging System (LI-COR, Biosciences). Finally, the membranes 
were scanned with the Odyssey® software and the amount of protein was quantified with ImageJ and 
normalized to a constitutively expressed protein, such as actin or tubulin.  
Table 3.4. Secondary antibodies used for Western blot. 
Secondary antibody Type Origin Dilution % BSA (in 
TTBS) 
Anti-Mouse IRDye®680 Donkey polyclonal LI-COR (926-68072) 1:10000 1 
Anti-Mouse IRDye®800 Donkey polyclonal LI-COR (926-32212) 1:10000 1 
Anti-Rabbit IRDye®680 Donkey polyclonal LI-COR (926-68073) 1:10000 1 
Anti-Rabbit IRDye®800 Donkey polyclonal LI-COR (926-32213) 1:10000 1 
 
3.5. ENCODE ANALYSIS  
The Encyclopedia of DNA Elements (ENCODE) is a public research consortium funded by the 
National Human Genome Research Institute (NHGRI) and it is aimed at identifying all functional elements 
in the human and mouse genomes. All ENCODE production data is submitted to the Data Coordinating 
Center at the University of California, Santa Cruz (UCSC). The human assembly of February 2009 
(GRCh37/hg19) of the UCSC Genome Browser (https://www.genome.ucsc.edu/) was used in this work.  
On one hand, chromatin immunoprecipitation sequencing (ChIP-seq) data were used to identify 
CTCF binding sites to the regulatory regions of the TFs involved in erythroid differentiation. This analysis 
was performed, not only in K562, but also in other human cell lines, to see if the interactions were cell type-
specific or if, however, they were conserved among different cell lines. ENCODE analysis for the subunit 
of cohesin complex Rad21 was also carried out to confirm the predicted CTSs.  
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On the other hand, Chromatin Interaction Analysis with Paired-End-Tag sequencing (ChIA-PET) 
data were used to analyze the genome-wide long-range chromatin interactions bound by CTCF, involving 
the CTCF binding site to the erythroid genes and other CTCF binding site (CTS). This analysis was also 
performed in K562 and other human cell lines available to make the comparison. 
Finally, Histone Modifications by ChIP-seq from ENCODE in the CTCF binding site to the genes 
of interest were analyzed. Three active histone marks (H3K4me1, H3K4me3 and H3K9Ac) and one 
repressive histone mark (H3K27me3) were analyzed in all human cell lines available.  
3.6. CBIOPORTAL ANALYSIS 
The cBioPortal for Cancer Genomics (http://cbioportal.org) provides genomics data from different 
large-scale projects, including The Cancer Genome Atlas (TCGA) and the International Cancer Genome 
Consortium (ICGC). Three studies of AML were used in this work: AML (OHSU, Nature 2018), AML 
(TCGA, PanCancer Atlas) and Pediatric AML (TARGET, 2018). Ten genes were queried for mutations 
and copy number alterations: CTCF, ETS1, MYB, GATA2, HEY1, LMO2, KLF1, NFE2L2, TCF3 and MYC. 
The portal shows different results:  
• OncoPrint was used to analyze the genomic alterations in queried genes across the samples, including 
missense mutations, nonsense mutations, truncating mutations, amplifications, and deletions.  
• The Mutual Exclusivity tab was used to analyze if two mutations tend to be mutually exclusive or, 
instead, two genetic alterations of different genes occurred simultaneously in the same sample.  
• The Mutations tab was used to analyze the position of each mutation in the queried genes and their 
frequency, as well as the amino acid change in the protein sequence. Cancer hotspots were further 
analyzed in the website https://www.cancerhotspots.org/ and OncoKB (https://www.oncokb.org/) was 
used to find more information about specific alterations. Additionally, those positions were localized 
in the UCSC Genome Browser to search for possible correlations between mutations in erythroid 
transcription factor genes and CTCF binding or chromatin interactions in AML. 
• The Overall survival graph was used to compare the overall survival of patients without mutations 
and the survival or patients with mutations in the genes of interest.  
• The CN (copy number) segment data was downloaded and visualized in the Integrative Genomics 
Viewer (IGV) in order to analyze the copy-number status of all queried genes. IGV provides a 
quantitative result of the cases with amplifications and deletions in the genes of interest.  
• The RNA seq data were analyzed to determine if the genetic mutations in the queried genes encompass 
changes in the mRNA expression compared with the average of the group. 
3.7. STATISTICAL ANALYSIS 
Data were represented as the mean of two or three independent experiments or one single 
experiment. Error bars represent the positive and negative standard deviation. The significance of 
differences was determined by the unpaired Student´s t-test. The differences were considered statistically 
significant when p<0.05 (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).  
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4. RESULTS 
4.1. EFFECTS OF CTCF DOWNREGULATION IN THE ERYTHROID CELL 
DIFFERENTIATION  
K562 cells can be induced to differentiate into several hematopoietic pathways in response to the 
treatment with different drugs (Torrano et al., 2005). For example, K562 can be differentiated into the 
erythroid lineage by treatment with Ara-C (Delgado et al., 1995; Torrano et al., 2005) or Imatinib (Gómez-
Casares et al., 2013). To know more about the role of CTCF in erythropoiesis, we aimed to down-regulate 
the expression of CTCF in K562 cells and analyze erythroid differentiation upon induction by treatment. 
First, we produced lentiviral particles containing a specific shRNA for CTCF gene (shCTCF) and for the 
corresponding empty vector pLKO (EV). K562 cells were infected with the lentiviral particles, selected 
with puromycin for two days and induced for erythroid differentiation with 1 μM Ara-C and 0.5 μM 
Imatinib (Figure 4.1a). CTCF downregulation was assessed by RT-qPCR (Figure 4.1b) and Western blot 
(Figure 4.1c). CTCF levels decreased in K562 cells infected with pLKO shCTCF, compared with those 
infected with the empty vector, and the downregulation was maintained for 3 days. Although there was a 
slightly reduction in CTCF levels upon differentiation with the empty vector, the reduction of CTCF was 
strongly higher with shCTCF.  
 
Figure 4.1. Assessment of CTCF downregulation in K562 cells upon erythroid differentiation. a) Schematic 
representation of the experiment, including the infection with lentiviral particles pLKO empty vector (EV) and pLKO 
shCTCF, the selection with puromycin for 48 hours, the induction of erythroid differentiation with 1 μM Ara-C or 0.5 
μM Imatinib and its subsequent analysis. b) Assessment of CTCF downregulation in K562 cells at day 0 (left) and its 
maintenance for 3 days (right) with mRNA expression of CTCF analyzed by RT-qPCR. Expression was normalized 
against RPS14 levels. Bars indicate mean of three experiments (Day 0) ± s.d. or one representative experiment (Days 
1, 2 and 3). Significance difference (**, p<0.01) from the untreated cells. c) Assessment of CTCF downregulation in 
K562 cells and its maintenance for 3 days with protein expression levels of CTCF analyzed by Western blot. Actin levels 
were used as loading control. Densitometry values are shown at the bottom, normalized to the control. C+, 293T cells 
transfected with pcDNA-CTCF as positive control. 
Cell proliferation was analyzed by cell counting until 3 days after induction of differentiation and 
untreated cells infected with the empty vector were considered the control (Figure 4.2a). On one hand, the 
cells that growth faster were K562 cells infected with the EV and untreated. Both Ara-C and Imatinib 
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treatments inhibited cell proliferation in K562 cells almost completely, compared to the control. Imatinib 
induced cell death the last day of treatment, as previously observed. On the other hand, CTCF 
downregulation provoked a slight reduction in cell proliferation, highlighting that CTCF is required for cell 
survival and proliferation.  
 
Figure 4.2. Effects of CTCF downregulation on erythroid differentiation of K562 cells. a) Cell proliferation curves for 
K562. 2.5 x 10⁵ cells were seeded, infected with pLKO EV or shCTCF and treated with 1 μM Ara-C or 0.5 μM Imatinib 
for 3 days. Bars indicate mean ± s.d. of 3 independent experiments. b) Benzidine test of K562 cells infected with pLKO 
EV or shCTCF and treated as above. Under the bar charts, pictures taken during benzidine test for K562 cells infected 
with pLKO EV at day 3 of treatment are shown. Bars indicate mean ± s.d. of 2 or 3 independent experiments. 
Significance difference (*, p<0.05; **, p<0.01) from the untreated cells (blue asterisks) or from the pLKO EV treated 
cells (red asterisks). c) Protein expression of γ-globin and GATA1 analyzed by Western blot after infection of K562 cells 
with pLKO EV or shCTCF and treatment with Ara-C and Imatinib for 3 days. Actin or tubulin levels were used as loading 
control. Densitometry values are shown at the bottom, normalized to the control. 
We assessed the erythroid differentiation using the benzidine test that analyzes hemoglobin 
production, exclusive of erythroid cells (Figure 4.2b). We confirmed the erythroid differentiation induced 
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by Ara-C and Imatinib in K562 cells up to 3 days with an increase in the percentage of benzidine positive 
cells compared to the untreated cells that was statistically significant for the day 3 of treatment. The effect 
of Imatinib was higher than the effect of Ara-C and the increase in the percentage of benzidine positive 
cells was gradual. Regarding with the changes in cell morphology and size, we observed that the cells 
treated with Ara-C, in addition to becoming blue, were bigger than the untreated cells and the cells treated 
with Imatinib were smaller.  
Furthermore, there was a reduction of benzidine positive cells in the cells infected with shCTCF 
compared to the ones infected with the EV at day 0, before the treatment with Ara-C or Imatinib. When we 
compared the K562 cells infected with shCTCF with the ones infected with the EV at day 3 of treatment 
with Ara-C or Imatinib, we observed a significant reduction in the percentage of benzidine positive cells 
upon CTCF downregulation. 
Additionally, erythroid differentiation was assessed by detecting the hemoglobin protein, which is 
exclusive of erythroid cells, by Western blot (Figure 4.2c). The expression of the γ-globin increased upon 
Ara-C and Imatinib treatment within 3 days compared with untreated cells, while γ-globin levels remained 
low upon CTCF downregulation. We analyzed the expression of another key erythroid marker, GATA1, 
which also decreased upon CTCF downregulation. 
Taken together, these results show that CTCF downregulation strongly reduces the percentage of 
hemoglobin producing cells and the protein levels of erythroid markers, indicating that CTCF 
downregulation could inhibit erythroid cell differentiation induced by Ara-C and Imatinib and spontaneous 
erythroid differentiation of untreated cells. Therefore, CTCF seems to be necessary for erythroid 
differentiation of K562 cells.  
In order to confirm the role of CTCF in erythropoiesis, similar experiments were performed with 
CD34+ progenitor cells obtained from cord blood of newborns, as a more physiological model. First, we 
isolated the mononuclear cells by density gradient centrifugation on Ficoll and then we purified CD34+ 
cells using magnetic beads. Expanded CD34+ cells were treated with Epo to induce erythroid 
differentiation, which was confirmed with the benzidine test and the expression of γ-globin and GATA1 
proteins by Western blot (data from Lorena García PhD Thesis). In order to study the effects of CTCF 
downregulation, CD34+ cells were infected with inducible lentiviral particles containing pTRIPTZ EV and 
pTRIPTZ shCTCF and selected for puromycin resistance for 2 days. Then, treatment with doxycycline was 
carried out for 2 days to induce the knock down of CTCF and erythroid differentiation was induced with 
Epo treatment for 5 days (Figure 4.3). In CD34+ cells infected with the EV, independently of doxycycline 
induction, we observed erythroid differentiation, as we expected. In CD34+ infected with shCTCF, we 
observed erythroid differentiation without doxycycline induction, but erythroid differentiation was 
inhibited with doxycycline induction, that is, upon CTCF downregulation (these are preliminary data 
obtained by Lorena Garcia that I couldn’t pursue and extend given the extraordinary sanitary situation). 
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Figure 4.3. Effects of CTCF downregulation on erythroid differentiation of CD34+ cells. Schematic representation of 
the experiment, including the infection with lentiviral particles pTRIPTZ empty vector (EV) and pTRIPTZ shCTCF, the 
selection with puromycin for 48 hours, the induction of CTCF downregulation with doxycycline (dox) for 48 hours and 
the erythroid differentiation with Erythropoietin (Epo). 
Taken together, our results reveal that CTCF downregulation, with constitutive or inducible 
systems, inhibits erythroid differentiation in K562 and primary CD34+ cells, highlighting the role of CTCF 
in the regulation of erythropoiesis. 
4.2. REGULATION OF ERYTHROID TRANSCRIPTION FACTORS MEDIATED BY CTCF 
 Erythroid genes mRNA expression 
Once we have demonstrated that CTCF has an essential role in erythroid differentiation, we aimed 
to analyze how CTCF modulates the expression of certain erythroid genes. Previous work of our group 
revealed, with microarray analysis, that CTCF overexpression in K562 cells modulates the expression of 
genes encoding, among others, several transcription factors that determine erythroid lineage differentiation.  
In this work, we selected some important transcription factors implicated in erythroid 
differentiation: 4 TFs that inhibit erythroid differentiation (ETS1, MYB, GATA2 and HEY1) and 4 that 
induce erythroid differentiation (LMO2, KLF1, NFE2L2 and TCF3). We first analyzed their mRNA 
expression upon induction of erythroid cell differentiation with Ara-C or Imatinib for the 3 days of 
treatment, and the results that were more consistent with previous results of our group were represented in 
Figure 4.4a. As preliminary results, we observed a reduction in the expression of ETS1, MYB, GATA2 and 
HEY1 upon differentiation and an increase in the expression of LMO2 and KLF1. In the case of NFE2L2, 
its expression did not change upon differentiation, and TCF3 expression was slightly increased with Ara-C 
treatment and did not change with Imatinib. In general, these results are in concordance with the role of 
those genes during differentiation although more experiments are needed to confirm them. 
We next analyzed the effect of CTCF downregulation in the mRNA expression of erythroid 
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transcription factor genes, prior to Ara-C or Imatinib treatment (day 0 of treatment) (Figure 4.4b). Because 
of the role of CTCF in erythropoiesis, we expected that the expression of the genes that ihibit erythroid 
differentiation decreased upon CTCF downregulation and the expression of those that induce erythroid 
differentiation increased. As preliminary results, we observed a reduction in the expression of MYB, HEY1, 
LMO2 and KLF1 upon CTCF downregulation and an increase in the expression of NFE2L2, while the 
expression of ETS1, GATA2 and TCF3 have hardly changed.  
 
Figure 4.4. Erythroid genes mRNA expression. mRNA expression levels of ETS1, MYB, GATA2, HEY1, LMO2, KLF1, 
NFE2L2 and TCF3 analyzed by RT-qPCR in K562 cells upon: a) erythroid differentiation induced by treatment with 1 
μM Ara-C for 72 hours or with 0.5 μM Imatinib for 24 (left) or 48 (right) hours, b) infection of K562 cells with pLKO EV 
or pLKO shCTCF without Ara-C or Imatinib treatment, and c) infection of K562 cells with pLKO EV or shCTCF and 
treated with 1 μM Ara-C for 72 hours or with 0.5 μM Imatinib for 48 hours. Expression was normalized against RPS14 
levels. Bars indicate mean of two experiments or one representative experiment. mRNA expression values were 
relativized to the values obtained for untreated cells infected with pLKO EV that are represented in b). 
In order to better stablish the role of CTCF during erythroid cell differentiation, we analyzed the 
effect of CTCF downregulation in the mRNA expression of erythroid transcription factor genes in K562 
cells treated with 1 μM Ara-C for 72 hours or with 0.5 μM Imatinib for 48 hours (Figure 4.4c). As 
preliminary results, we observed an increase in the expression of the genes that inhibit erythroid 
differentiation (ETS1, MYB and GATA2) in cells with shCTCF treated with Ara-C, while a decrease in 
HEY1 expression was observed. A reduction in the expression of the genes that induce erythroid 
differentiation (LMO2, KLF1, NFE2L2 and TCF3) was observed. In K562 cells treated with Imatinib, we 
observed an increase in the expression of ETS1 upon CTCF downregulation and a decrease in the expression 
of GATA2, LMO2 and KLF1. The expression of MYB, HEY1, NFE2L2 and TCF3 has hardly changed upon 
Imatinib treatment in the cells with downregulated CTCF. Nevertheless, those are preliminary results and 
those experiments should be repeated a few times to perform statistical analysis. 
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 Erythroid transcription factors protein expression  
In order to confirm and extend the results obtained with RT-qPCR, we next aimed to analyze by 
Western blot the effects of CTCF downregulation on the protein expression levels of some erythroid 
transcription factors, such as LMO2, MYB and HEY1 during erythroid differentiation induced by Ara-C 
(Figure 4.5a) and Imatinib (Figure 4.5b). When we compared the K562 cells infected with shCTCF with 
the ones infected with the EV, prior to Ara-C or Imatinib treatment, we observed a decrease in LMO2 and 
MYB protein levels. LMO2 levels increased during erythroid differentiation induced by Ara-C and 
Imatinib, as we expected due to its role in the induction of erythropoiesis. When we downregulated CTCF, 
we observed an increase in the LMO2 protein levels upon erythroid differentiation induced by Ara-C and 
Imatinib during the 3 days of the treatment.  
MYB protein levels were reduced during erythroid cell differentiation induced by Ara-C and 
Imatinib for 3 days, as we expected due to its role in the inhibition of erythropoiesis. When we 
downregulated CTCF, we observed a reduction in MYB protein levels upon erythroid differentiation 
induced by Ara-C and Imatinib during the 3 days of the treatment.  
The expression of HEY1 has been normalized to K562 cells infected with pLKO EV treated with 
Ara-C at day 1 of treatment. We observed a slightly decrease in the expression of HEY1 protein levels in 
the K562 cells infected with the EV during erythroid differentiation induced by Ara-C and an increase in 
the ones infected with shCTCF.  
 
Figure 4.5. Effect of CTCF downregulation on erythroid transcription factors protein expression. Protein expression 
of CTCF, LMO2, MYB, HEY1 and MYC analyzed by Western blot after infection of K562 cells with pLKO EV or shCTCF 
and treated with a) 1 μM Ara-C or b) 0.5 μM Imatinib for 3 days. Actin or tubulin levels or coomasie-blue stained gel 
were used as loading control. Densitometry values are shown at the bottom, normalized to the control. C+, 293T cells 
transfected with pCEFL-CTCF as positive control of CTCF and Jurkat cells as positive control of MYB and MYC. 
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We also analyzed the expression of MYC protein because it plays an important role during cell 
proliferation and differentiation and it has been widely studied in our group. Previous results of our group 
confirmed that MYC expression decreases during erythroid differentiation (Delgado et al., 1995). MYC 
levels decreased upon CTCF downregulation and this reduction was maintained during erythroid 
differentiation induced by Ara-C.  
4.3. ENCODE ANALYSIS IN K562 AND OTHER HUMAN CELL LINES 
We have demonstrated that CTCF has an essential role in erythroid differentiation and we 
hypothesized that CTCF could be regulating specific erythroid genes. Therefore, we analyzed in silico the 
CTCF binding to the regulatory regions of selected genes encoding erythroid transcription factors using 
ENCODE Project data available on the UCSC Genome Browser.  
 CTCF binding sites to erythroid genes 
We analyzed the ChIP-seq data published in the ENCODE project to identify possible CTCF 
binding sites (CTSs) to the selected erythroid genes: ETS1, MYB, GATA2, HEY1, LMO2, KLF1, NFE2L2 
and TCF3 in five human cell lines (Figure 4.6a, Supplementary figures S1-S7 a) (Due to space 
limitations, most figures are shown as Supplementary information). 
• GATA2 is a TF highly expressed in HSCs that is repressed by GATA1 during erythropoiesis. 
ENCODE ChIP-seq analysis revealed a CTCF binding site 5 kb upstream GATA2 gene in K562 cells 
(Figure 4.6a). This CTS is also a binding site of the Rad21 subunit of cohesin complex, which strongly 
supports CTCF binding in this position. This CTS is conserved in lymphoblastoid (GM78), lung 
adenocarcinoma (A549), lung fibroblast (IMR90) and neuroblastoma (SK-N-SH) cell lines. 
• ETS1 is a TF that inhibits erythroid differentiation, and, during erythropoiesis, its expression must be 
downregulated. ENCODE ChIP-seq analysis revealed a CTCF/Rad21 binding site 43 kb upstream 
ETS1 gene (between ETS1 and FLI1 genes) in K562 cells that is conserved in different cell lines 
(Supplementary Fig. S1a).  
• MYB is a TF that is highly expressed in HSCs and must be downregulated during erythroid cell 
differentiation. ENCODE ChIP-seq analysis revealed a CTCF/Rad21 binding site in the intron 1 of 
MYB gene (2.5 kb downstream from the TSS) in K562 cells (Supplementary Fig. S2a). This CTS is 
conserved in different cell lines. However, in some of them, such as A549, IMR90 and SK-N-SH, a 
novel CTS 15.5 kb upstream MYB gene show a higher peak than the CTS in the intron 1.  
• HEY1 is a TF that inhibits the expression of GATA1, maintaining an undifferentiated state of erythroid 
precursors. ENCODE ChIP-seq analysis revealed a CTCF/Rad21 binding site in the exon 5 of HEY1 
gene (2.1 kb downstream from the TSS) in K562 cells that is conserved in different cell lines 
(Supplementary Fig. S3a). 
• LMO2 is a non-DNA binding component of the CEN that promotes the expression of erythroid genes. 
ENCODE ChIP-seq analysis revealed a CTCF/Rad21 binding site 34 kb downstream LMO2 gene in 
K562 cells that is conserved in different cell lines (Supplementary Fig. S4a). 
• KLF1 is a TF of the CEN that is essential for terminal erythroid cell differentiation. ENCODE ChIP-
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seq analysis revealed a CTCF/Rad21 binding site in the exon 2 of KLF1 gene in K562 cells, which is 
conserved in different cell lines (Supplementary Fig. S5a). 
• NRF2, encoded by NFE2L2, is an erythroid TF involved in the regulation of β-globin gene 
transcription. There is a CTCF/Rad21 binding site in the intron 1 of NFE2L2 gene in K562 cells that 
is conserved in different cell lines (Supplementary Fig. S6a). Some cell lines, including GM, A549, 
IMR90 and SK-N-SH, show other CTS in the exon 1 of NFE2L2 gene, higher than the CTS in the 
intron 1 of NFE2L2. 
• TCF3, also called E2A, is a TF that regulates HSC differentiation and interacts with the CEN to 
promote erythroid gene transcription. There is a CTS 23 kb upstream TCF3 gene in K562 cells, which 
is also a Rad21 binding site, and it is conserved in different cell lines (Supplementary Fig. S7a). 
 
Figure 4.6. Analysis of CTCF binding to GATA2 gene with UCSC Genome Browser. a) ENCODE analysis showing ChIP-
seq profile of CTCF and Rad21 for GATA2 gene in chromosome 3 from 5 human cell lines. CTCF binding site 5 kb 
upstream GATA2 gene is shown with a red arrow. b) ChIA-PET interactions from the GATA2 CTS that are conserved 
are shown as red arcs and interactions that are not conserved are shown as blue arcs. c) Histone modifications by 
ChIP-seq from ENCODE in the GATA2 CTS (highlighted in blue) in different cell lines. 
Once identified the CTCF binding sites to the selected erythroid transcription factor genes, the 
next aim should be to perform chromatin immunoprecipitation experiments to confirm the CTCF 
occupancy at these sites in K562 cells during erythroid differentiation as well as in other cell lines. Part of 
these experiments in K562 have been already performed in our lab. 
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 Chromatin interactions involving erythroid genes 
We analyzed the ChIA-PET data published in the ENCODE project to identify possible 
interactions involving the previously identified CTSs around erythroid genes (Figure 4.6b, 
Supplementary figures S1-S7 b). 
• ENCODE ChIA-PET data for GATA2 gene revealed three interactions including the CTS 5 kb 
upstream GATA2, all of them located downstream (75, 280 and 335 kb) GATA2 in K562 cells (Figure 
4.6b, red arcs). The smallest loop includes DNAJB8 gene and the biggest one includes also EEFSEC 
gene. The longest loop is not conserved in breast adenocarcinoma (MCF-7) cell line, which present six 
new interactions around GATA2 (blue arcs).  
• ENCODE ChIA-PET data for ETS1 revealed two interactions between the CTS upstream ETS1 in 
K562 cells and two CTSs located downstream (440 and 300 kb) ETS1 gene (Supplementary Fig. 
S1b). Because the loops contain ETS1, CTCF may function as an insulator between ETS1 and FLI1 
genes. These two interactions are conserved in MCF-7 cells, that present two new interactions.  
• ENCODE ChIA-PET data for MYB revealed one interaction involving the CTS in the intron 1 of MYB 
and one CTS 40 kb upstream MYB in K562 cells (Supplementary Fig. S2b). This loop is conserved 
in MCF-7 cells, and in this cell line there was a new interaction with a CTS downstream MYB. 
• ENCODE ChIA-PET data for HEY1 revealed one loop involving the CTS in the exon 5 of HEY1 and 
other CTS 250 kb upstream HEY1 in K562 cells (Supplementary Fig. S3b). The loop also contains 
the MRPS28 gene (mitochondrial ribosomal protein S28). The interaction is conserved in MCF-7 cell 
line, and there is a new loop involving the CTS in the exon 5 of HEY1. 
• ENCODE ChIA-PET data for LMO2 revealed four loops that involve CTS 34 kb downstream LMO2 
in K562 cells, all of them are located upstream LMO2 (Supplementary Fig. S4b). Three interactions 
involving the CTCF binding site downstream LMO2 are conserved in MCF-7 cell line, but the smallest 
loop is not conserved and there is a new interaction, which is longer. 
• ENCODE ChIA-PET data for KLF1 revealed one loop formed between the CTS in the exon 2 of KLF1 
and a CTS located 34 kb upstream KLF1 in K562 cells (Supplementary Fig. S5b). The loop also 
contains the GCDH gene (glutaryl-CoA dehydrogenase) and SYCE2 gene (Synaptonemal complex 
central element protein 2). The interaction involving the CTS in the exon 2 of KLF1 gene is not 
conserved in MCF-7 cell line, which have a new longer interaction.  
• ENCODE ChIA-PET data for NFE2L2 revealed two interactions involving the CTS in the intron 1 of 
NFE2L2 gene in K562 cells. One loop is formed with a CTS in the exon 1 of NFE2L2 gene and other 
loop is formed with a CTS 105 kb downstream NFE2L2 gene (Supplementary Fig. S6b). The biggest 
loop includes HNRNPA3 gene (pre-mRNA splicing). Any interaction was observed involving the CTS 
in the intron 1 of NFE2L2 gene in MCF-7 cells. However, two loops are formed around the NFE2L2 
gene in MCF-7 cells, involving the CTS in the exon 1 of NFE2L2. 
• ENCODE ChIA-PET data for TCF3 revealed seven interactions involving the CTS upstream TCF3 in 
K562 cells. Two loops are formed with two CTSs located downstream (100 and 43 kb) TCF3 gene and 
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five loops with CTSs located upstream (1, 116, 141, 142 and 163 kb) TCF3 gene. In the loops that are 
formed with CTSs located downstream TCF3, CTCF could act as an insulator between TCF3 and 
ONECUT3, ATP8B3 and REXO1 genes. Four of the interactions are conserved in MCF-7, that have 
two new loops (Supplementary Fig. S7b). 
In summary, different long-range interactions involving CTCF binding sites have been identified 
in the erythroid transcription factor genes. It should be interesting to analyze possible changes in these 
interactions during erythroid differentiation although these experiments are out of the scope of this work. 
 Histone marks in CTSs of erythroid genes 
We analyzed histone modifications levels in the CTSs of erythroid genes obtained by ChIP-seq 
from the ENCODE project (Figure 4.6c, Supplementary figures S1-S7 c). Three active (H3K4me1, 
H3K4me3 and H3K9Ac) and one repressive (H3K27me3) histone marks have been reported in K562 cells.  
• The CTS in GATA2 is not enriched in any histone modification in K562 cells (Figure 4.6c), but 
pancreatic adenocarcinoma (PANC-1) cell line is enriched in active mark H3K4me3.  
• The CTS in ETS1 is not enriched in any histone mark in K562 cells (Supplementary Fig. S1c). 
However, this site is enriched in H3K4me1 in PANC-1 cells and peripheral blood mononuclear cells 
(PBMC). Lung malignant pluripotent embryonal carcinoma (NT2-D1) cells have small peaks of 
H3K9Ac and H3K27me3. 
• The CTS in MYB is enriched in active histone modifications (H3K4me3 and H3K9Ac) in K562 cell 
line (Supplementary Fig. S2c). PBMC are also enriched in H3K4me3 and, additionally, they are 
enriched in H3K4me1. However, NT2-D1 cells are enriched in repressive mark H3K27me3. 
• The CTS in HEY1 is enriched in histone modifications related with active genes (H3K4me1 and 
H3K9Ac) in K562 cells (Supplementary Fig. S3c). PBMC are also enriched in H3K4me1, but they 
are enriched in repressive H3K27me3 too. PANC-1 are enriched in active mark H3K4me3. 
• The CTS in LMO2 is not enriched in any histone mark in any cell line (Supplementary Fig. S4c).  
• The CTS in KLF1 is enriched in the three active histone marks in K562 cells (Supplementary Fig. 
S5c). PBMC are also enriched in H3K4me1 and H3K9Ac, and PANC-1 are enriched in H3K4me3. 
NT2-D1 are enriched in active marks, but they are enriched in repressive H3K27me3 too. 
• The CTS in NFE2L2 is enriched in active histone modifications (H3K4me1 and H3K9Ac) in K562 
cells (Supplementary Fig. S6c). PBMC and PANC-1 are also enriched in active mark H3K4me1.  
• The CTS in TCF3 is enriched in active histone marks (H3K4me1, H3K4me3 and H3K9Ac) in K562 
cells (Supplementary Fig. S7c). PBMC cells are also enriched in H3K4me1 and PANC-1 cells are 
enriched in H3K4me3. NT2-D1 cells are also enriched in active marks (H3K4me3 and H3K9Ac), 
however they are enriched in repressive mark H3K27me3 too.  
Once we have made in silico predictions of histone marks in the CTCF binding sites to erythroid 
genes, we would have performed ChIP experiments to analyze changes of histone modifications in those 
CTSs during erythroid differentiation and upon CTCF downregulation. 
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4.4. ANALYSIS OF GENETIC ALTERATIONS IN CTCF OR ERYTHROID GENES IN 
LEUKEMIA PATIENTS  
In order to search for possible correlations between CTCF expression or mutations or CTCF 
binding site mutations and erythroid transcription factors expression or mutations, a combined study of 
hematological cancers was performed with cBioPortal. AML was chosen among all leukemia types because 
in this work we were interested in the differentiation of myeloid lineage. A query of genomic data was 
made for the analysis of ten genes (CTCF, ETS1, MYB, GATA2, HEY1, LMO2, KLF1, NFE2L2, TCF3 and 
MYC) in a combined study including 3 studies of AML (Figure 4.7a). A total of 1897 samples from 1661 
patients were analyzed and profiled for copy number alterations and mutations, among others. 
CTCF mutations and deletions mostly result in loss-of-function and predominantly occur in worse 
prognosis subtypes of cancer, as it has been previously described for endometrial carcinoma (Marshal et 
al., 2017). We found that the overall survival of AML patients with alterations in CTCF was much lower 
than the survival of the unaltered group (11 vs. 55 median months overall survival) (Figure 4.7b).  
Overall, queried genes were altered in 5% of the patients and GATA2 was the most frequently 
mutated gene (Figure 4.7c). The most frequent alterations in those genes included genetic amplifications, 
deletions, missense mutations (very common in MYC and GATA2), and some truncating mutations were 
also found. We focused on CTCF, that was altered in 0.9% of the samples. Truncating mutations in CTCF 
are considered as driver mutations because they give rise to an incomplete protein and could play a role in 
AML development. Additionally, patients with this type of mutations deceased. On the other hand, 
deletions of CTCF and missense mutations that change one amino acid of CTCF protein were found in 
patients that survived and in patients that deceased.  
Since DNA copy number variations (CNVs) have been strongly associated with cancer, we 
analyzed the CNVs of the queried genes, and we observed that CTCF was amplified in 2% of the samples 
and deleted in 3% of them. CTCF alterations were related with a lower CTCF mRNA expression analyzed 
by RNA-seq in the great majority of the cases (Figure 4.7d). 
We next aimed to examine CTCF alteration frequency depending on cancer type and we observed 
that CTCF gene was altered in 0.74% of 1088 cases of AML, with half of the alterations being mutations 
and the other half deep deletions (Figure 4.7e). Additionally, a truncating mutation of CTCF was observed 
in 16.67% of 6 cases of generically called myeloproliferative neoplasms (not shown). Further analysis on 
AML subtypes showed that CTCF mutation frequency was higher in AML not otherwise specified (NOS), 
which includes those AML subtypes not associated with recurrent genetic abnormalities. CTCF gene was 
also mutated in AML with myelodysplasia-related changes, which has a poor prognosis, and in AML with 
mutated NPM1, with favorable outcomes. All CTCF deletions and one mutation were detected in AML 
(subtype not specified). Furthermore, CTCF was altered neither in AML with recurrent genetic 
abnormalities, nor in AML with chromosomal translocations or inversions.  
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Figure 4.7. Analysis of mutations in hematological cancers with cBioPortal. a) Query of genomic data in cBioPortal 
for the analysis of ten genes: CTCF, ETS1, MYB, GATA2, HEY1, LMO2, KLF1, NFE2L2, TCF3 and MYC in a combined study 
of AML. b) Survival analysis of AML cancer samples with (yellow) or without (blue) CTCF genetic alterations. c) The 
OncoPrint tab shows a visual summary of the genomic alterations in all queried genes across the study. Each row 
represents a gene and each column represents a sample. d) mRNA expression levels of CTCF by RNA-seq in relation 
to its copy-number status in each sample from AML (TCGA PanCancer Atlas) study. 1661 AML cases are shown. e) 
CTCF alteration frequency for leukemia (left) and detailed AML subtypes (right) including mutations (green) and deep 
deletions (blue). f) Position and frequency of CTCF mutations. Flames represent the most recurrent mutations (cancer 
hotspots).  
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Because biological processes in cancer are often deregulated through different genes, we aimed to 
analyze the mutual exclusivity events or, by contrast, co-occurrence in queried genes. Most of the samples 
showed mutations in a single gene, except for some cases such as co-occurrence of mutations in MYB and 
NFE2L2. Although it was not significant, alterations in CTCF appeared to be exclusive, and only one 
sample showed deletion of both CTCF and NFE2L2 genes (Table 4.1).  
Table 4.1. Mutual exclusivity tab for CTCF alterations. 
A B Neither A Not B B Not A Both q-Value Tendency 
CTCF NFE2L2 898 7 2 1 0.295 Co-occurrence 
CTCF GATA2 866 8 34 0 0.999 Mutual exclusivity 
CTCF MYC 890 8 10 0 0.999 Mutual exclusivity 
CTCF MYB 891 8 9 0 0.999 Mutual exclusivity 
CTCF TCF3 895 8 5 0 0.999 Mutual exclusivity 
CTCF ETS1 896 8 4 0 0.999 Mutual exclusivity 
CTCF KLF1 899 8 1 0 0.999 Mutual exclusivity 
CTCF HEY1 899 8 1 0 0.999 Mutual exclusivity 
CTCF LMO2 899 8 1 0 0.999 Mutual exclusivity 
 
We next examined the position of the mutations and we found 5 mutations in CTCF, one of them 
in the N-terminal domain, three in the zinc fingers and one in a spacer region (Figure 4.7f). The mutations 
in the positions 261 in the N-terminal domain, and 363 in the ZF4, are splice-site mutations that can disrupt 
RNA splicing resulting in an abnormal CTCF protein. The mutation R339Q in the ZF3 corresponds to a 
putative driver missense mutation. The mutation R377H is localized in the spacer region between ZFs 4 
and 5, also corresponds to a missense mutation and it is a cancer hotspot that has been reported as a recurrent 
mutation in some cancers. The mutation of the arginine 457 is located in the ZF7 that interacts with 5´ 
sequence of DNA and it is a truncating mutation. This last mutation was termed as “likely oncogenic” and 
it has been reported in endometrial cancer (Zighelboim et al., 2014).  
Finally, we observed a mutation in the hairy orange motif of HEY1 (R123Q) that is included in 
the CTCF binding site to the exon 5 of this gene that has been previously found with the UCSC Genome 
Browser (Supplementary Fig. S3d). We analyzed mutations in other genes, such as MYB, GATA2 or MYC, 
but those regions did not appear to be relevant for CTCF binding, they were neither the CTCF binding sites 
nor the ends of the chromatin loops. 
5. DISCUSSION  
Red blood cells are generated through the differentiation and proliferation of hematopoietic stem 
cells during erythropoiesis. This process is controlled by a combination of transcription factors that regulate 
erythroid gene expression, and their dysregulation is associated with blood cell disorders. Human leukemia 
cell lines, such as K562, are commonly used in the study of erythroid differentiation. Multipotent K562 
cells, derived from CML, can be induced to differentiate into several hematopoietic pathways (Torrano et 
al., 2005). More specifically, erythroid differentiation can be induced in K562 cells using cytosine 
arabinoside (Ara-C) or Imatinib (Delgado et al., 1995; Gómez-Casares et al., 2013). Primary CD34+ 
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progenitor cells obtained from cord blood of newborns are used as a more physiological model and can be 
induced to differentiate into erythroid lineage with erythropoietin (Epo) treatment (Nandakumar et al., 
2016). In this work, erythroid differentiation was confirmed with an increase in hemoglobin accumulation, 
accompanied by a reduction of cell growth and an increase in the expression of erythroid markers (γ-globin 
and GATA1). The results were consistent with those obtained previously by our group upon the treatment 
of K562 cells with Ara-C.  
CTCF is a zinc finger protein that interacts with many partners to perform multiple functions, 
including transcriptional activation or repression, chromatin insulation, chromatin looping, long-range 
interactions, epigenetic regulation. CTCF plays an essential role in hematopoiesis and has been shown to 
be differentially expressed and phosphorylated depending on the differentiation pathway of human myeloid 
leukemia cells (Delgado et al., 1999). Our group also described that CTCF overexpression promotes 
erythroid differentiation of K562 cells (Torrano et al., 2005). CTCF appears to be necessary for erythroid 
cell differentiation and globin genes expression (Kang et al., 2017; Stadhouders et al., 2012), but molecular 
mechanisms of this process are still unknown. 
To gain further insight into the regulation of erythropoiesis by CTCF, we aimed to downregulate 
CTCF expression in K562 cells. For that purpose, K562 cells were infected with lentiviral particles 
containing a constitutive vector with specific shRNA against CTCF and treated with Ara-C or Imatinib. 
We observed that cell proliferation was reduced upon CTCF downregulation, which is consistent with the 
requirement of CTCF for cell viability (Bailey et al., 2018). A reduction in hemoglobin producing cells and 
erythroid markers expression (γ-globin and GATA1) was also observed upon CTCF downregulation and 
did not increase after the treatment with Ara-C and Imatinib. Hou et al. (2010) also reported that CTCF 
reduction markedly reduces globin gene expression, however it did not affect the protein levels of the 
important globin gene activator GATA1 (Hou et al., 2010). Additionally, downregulation of CTCF with a 
doxycycline inducible system inhibits erythroid cell differentiation induced by Epo in primary CD34+ cells 
(preliminary data obtained by Lorena Garcia). Taken together, these results confirm that the reduction of 
CTCF inhibits spontaneous and induced erythroid cell differentiation and support that CTCF is required for 
erythropoiesis, which is consistent with previous results from our group (Torrano et al., 2005).  
Erythropoiesis is regulated by a core erythroid network of transcription factors (CEN) and 
interacting proteins that control erythroid genes expression. Previous results of our group indicated that 
CTCF overexpression modulates the expression of certain genes encoding erythroid TFs (unpublished 
data), that were analyzed in this work. We analyzed the mRNA expression of four transcription factors that 
inhibit erythroid differentiation (ETS1, MYB, GATA2 and HEY1) and four that induce erythroid 
differentiation (LMO2, KLF1, NFE2L2 and TCF3). We observed that the expression of those genes after 
the treatment with Ara-C and Imatinib is consistent with their role during erythroid cell differentiation, 
except for NFE2L2 and TCF3. Similarly, it has been reported that NFE2L2 was absent in very early stages 
of induced erythropoiesis and appeared at late stages (Mahajan et al., 2009). 
The reduction of CTCF alters the expression of erythroid TFs in K562 cells, which is consistent 
with CTCF requirement for erythropoiesis. As preliminary results, we observed a reduction in the 
expression of MYB, HEY1, LMO2 and KLF1 upon CTCF downregulation and an increase in the expression 
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of NFE2L2, while the expression of ETS1, GATA2 and TCF3 hardly changed. The reduction in the 
expression of MYB upon CTCF downregulation is consistent with the fact that MYB expression is regulated 
by CTCF interaction with LDB1 complexes around MYB gene (Stadhouders et al., 2012). Additionally, 
CTCF binding to LMO2 regulatory regions has been reported (Bhattacharya et al., 2012).  
Furthermore, we analyzed the changes in TFs expression after Ara-C or Imatinib treatment of 
K562 cells with downregulated CTCF and we observed that the results vary slightly depending on the 
treatment. On one hand, we observed an increase in the expression of the genes that inhibit erythroid 
differentiation (except HEY1) and a reduction in the expression of the genes that induce erythroid 
differentiation in cells with shCTCF treated with Ara-C, as we expected. On the other hand, we observed 
an increase in the expression of ETS1 and a decrease in the expression of GATA2, LMO2 and KLF1, while 
the expression of MYB, HEY1, NFE2L2 and TCF3 has hardly changed in K562 cells with shCTCF treated 
with Imatinib. Nevertheless, those are preliminary results and those experiments will be repeated. We 
confirmed by protein expression analysis that LMO2 levels increased during erythroid differentiation and 
were reduced upon CTCF downregulation. We also confirmed that MYB protein expression levels 
decreased during erythroid differentiation and were reduced upon CTCF downregulation, as we found by 
mRNA expression. We observed that HEY1 decreased during erythroid differentiation and increased with 
downregulated CTCF, which has not hardly changed in terms of mRNA expression.  
CTCF and cohesin co-occupy regulatory regions in the genome and mediate long-range chromatin 
interactions in a cell-type specific manner (Steiner et al., 2016). We used ChIP-seq data from the ENCODE 
project to identify possible CTCF binding sites (CTSs) to the regulatory regions of the erythroid genes in 
different hematopoietic and non-hematopoietic human cell lines. All CTSs were supported by cohesin 
complex subunit Rad21 binding. ChIA-PET data was used to find chromatin interactions around them. 
Active (H3K4me1, H3K4me3 and H3K9Ac) and repressive (H3K27me3) histone modifications were also 
analyzed.  
The expression of ETS1, MYB, GATA2 and HEY1 must be downregulated to allow erythroid cell 
differentiation (Perry & Soreq, 2002). We identified a CTS 43 kb upstream ETS1 gene, which could interact 
with two CTSs downstream ETS1 gene. CTCF could function as an insulator between ETS1 gene and 
another member of the ETS family, Friend leukemia integration 1 (FLI1). FLI1 is involved in 
erythroid/megakaryocytic differentiation and its expression is indicative of megakaryocyte cell, while 
blocking the erythroid differentiation (Doré & Crispino, 2011). We identified a CTS in the first intron of 
MYB gene, that has been previously reported (Stadhouders et al., 2012), and interacts with another CTS 
upstream MYB. We identified a CTS 5 kb upstream GATA2 gene that participates in different interactions 
with three CTSs located downstream GATA2 in K562 cells. The biggest loop includes GATA2, DNAJB8 
and EEFSEC, which could bring together regulatory elements of these genes. We identified a CTS in the 
exon 5 of HEY1 that interacts with another CTS upstream HEY1 gene in K562 cells and this loop includes 
MRPS28 gene.  
By contrast, LMO2, KLF1, NFE2L2 and TCF3 are required for erythroid differentiation (Love et 
al., 2014). We identified a CTS 34 kb downstream LMO2 that interacts with four CTSs upstream LMO2. 
There are different distal regulatory regions that modulate LMO2 expression and several CTSs upstream 
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LMO2 have been reported (Bhattacharya et al., 2012). CTCF may function as an insulator between LMO2 
and the neighbouring cell cycle associated protein 1 (CAPRIN1). We identified a CTS in the exon 2 of 
KLF1 that interacts with another CTS upstream KLF1, forming a loop that includes GCDH and SYCE2 
genes. KLF1 is necessary for the formation of chromatin loops around the β-globin gene mediated by CTCF 
(Kang et al., 2017), suggesting that CTCF binding to KLF1 gene could increase KLF1 expression and, as a 
result, β-globin gene expression. We identified a CTS in the intron 1 of NFE2L2 that interacts with two 
CTSs, one in the exon 1 of NFE2L2 and another downstream NFE2L2. Both interactions appear to be 
exclusive of K562 cells. We identified a CTS 23 kb upstream TCF3 that interacts with seven CTSs and is 
mainly enriched in active histone marks. CTCF could act as an insulator between TCF3 and ONECUT3, 
ATP8B3 and REXO1 genes depending on the cell type.  
In summary, we identified shared and non-shared chromatin interactions around erythroid genes 
in K562 cells and breast adenocarcinoma MCF-7 cell line, which is consistent with the cell-type specificity 
of certain chromatin interactions mediated by CTCF and cohesin (Steiner et al., 2016). We also found that 
the patterns of histone modifications in our CTSs were variable between different cell lines. As further 
experiments, ChIP experiments should be performed to analyze active (H3Ac and H3K4me2) and 
repressive (H3K9me3 and H3K27me3) histone marks in the CTCF binding sites to erythroid transcription 
factor genes, as it has been performed in our group for CTCF binding site to BCL6 (Batlle-López et al., 
2015). We would expect that CTCF downregulation reduced CTCF occupancy in all CTSs. Due to the 
important role of CTCF in erythropoiesis, we would also expect an increase in repressive histone marks 
and a reduction of active histone marks in the genes that induce erythroid differentiation when we decreased 
CTCF levels. We would expect the opposite effect in the genes that inhibit erythroid differentiation. 
Finally, we analyzed genetic alterations in CTCF and erythroid transcription factor genes in AML 
patients with cBioPortal, that have not already been reported (Debaugny & Skok, 2020; Voutsadakis, 2018). 
AML starts in the bone marrow form immature cells that develop into abnormal white blood cells. AML is 
a genetically and molecularly heterogeneous disease and, because the subtype of AML can be important to 
determine a patient´s prognosis, the World Health Organization classified AML in 2016 into several groups 
(American Cancer Society, 2018). We observed that CTCF mutations and deletions in AML patients 
decrease CTCF mRNA expression. It has been reported that CTCF hemizygous loss in human tumors may 
be related with different clinical outcomes (Kemp et al., 2015). We observed a reduction in the survival of 
AML patients with CTCF alterations, which is in concordance with the association between the reduced 
levels of CTCF and a poor survival of cancer patients reported in other studies (Kemp et al., 2015). CTCF 
loss of function observed in AML studies, mainly due to truncating mutations, supports its role as 
oncosuppressor gene during cancer development (Bailey et al., 2018; Filippova et al., 1998). We observed 
that most of the deletions encompass large portions on the long arm (q) of chromosome 16, not only CTCF 
deletion, as it was observed in endometrial cancer (Walker et al., 2015), and the deletion of these regions 
could include other tumor suppressor genes. Additionally, CTCF mutations rarely co-occur with mutations 
in the studied erythroid genes in the same patients. 
Mutations were observed in the N-terminal domain and ZF domain of CTCF, including the 
mutation in the position R339 that has been reported in Wilms tumor (Filippova et al., 2002); the mutation 
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R377H that is a cancer hotspot reported as a recurrent mutation in endometrial (Filippova et al., 2002; Oh 
et al., 2017), uterus, bowel and skin cancers (Chang et al., 2018); and the mutation in the position R457 
that has been reported in endometrial cancer (Zighelboim et al., 2014). The mutation R339Q in the ZF3 of 
CTCF eliminates the arginine at position 6 of the alpha helix that is contacting guanine, therefore may be 
critical for DNA recognition. The mutation R377H is localized in the spacer region between ZFs 4 and 5 
and does not directly affect the contact with DNA, but it could alter the formation of the ZFs. The mutation 
in the arginine 457, that does not directly interact with the DNA, is a nonsense mutation, which leads to a 
premature stop codon and may lead or not to a loss of binding. Cancer-associated CTCF stop codon 
mutations have been analyzed in many types of cancers, not including AML (Debaugny & Skok, 2020). 
The mutation in the N-terminal domain could affect the interaction of CTCF with distinct binding partners, 
and mutations in this domain have been reported in other cancers. In conclusion, the reduction in CTCF 
levels and function associated with mutations could modulate the expression of many genes with important 
roles in AML tumorigenesis, in part due to the alterations in chromatin looping mediated by CTCF, as it 
has been described in other cancers (Debaugny & Skok, 2020). 
6. CONCLUSIONS  
1. CTCF downregulation with constitutive or inducible systems based on siRNA inhibits erythroid 
differentiation in K562 cells and in primary CD34+ cells, indicating that CTCF is required for the 
erythropoiesis. 
2. The expression of erythroid transcription factors changed in K562 cells during erythroid differentiation 
according to their role during erythropoiesis, at both mRNA and protein levels. CTCF downregulation 
altered their expression after Ara-C and Imatinib treatment.  
3. CTCF binding to erythroid transcription factor genes participates in the formation of long-range 
chromatin interactions that differ between cell lines, suggesting a cell-type specific expression of 
erythroid transcription factors mediated by CTCF. 
4. CTCF expression is reduced in some AML cases and lower CTCF levels have been associated with 
lower AML survival. Therefore, CTCF could be implicated in the development of AML. 
7. FUTURE WORK 
In order to mechanistically unravel CTCF function as a transcriptional regulator of erythroid 
transcription factors, a summary of our future research could be:  
1. Further analyze mRNA and protein expression to verify preliminary results about the effects of CTCF 
downregulation on the expression of erythroid transcription factors during erythroid differentiation. 
2. Perform ChIP experiments to analyze CTCF occupancy and histone modifications at CTCF binding 
sites to the selected erythroid transcription factor genes in K562 cells during erythroid differentiation, 
as well as in other cell lines. 
3. Perform ChIP experiments for histones upon CTCF downregulation to analyze the role of CTCF on 
local chromatin structure in the CTCF binding sites to erythroid genes.  
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4. Extend cBioPortal analysis to search for possible alterations in CTCF or erythroid genes in other 
hematological malignancies, such as T-ALL, myeloproliferative neoplasms, and lymphomas. We 
could access to more data from other portals, including ICGC Data Portal, COSMIC or Tumorscape. 
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9. APPENDIX 
 
Supplementary Figure S1. Analysis of CTCF binding to ETS1 gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for ETS1 gene in chromosome 11 from 5 human cell lines. CTCF binding 
site 43 kb upstream ETS1 gene is shown with a red arrow. b) ChIA-PET interactions from the ETS1 CTS that are 
conserved are shown as red arcs and interactions that are not conserved are shown as blue arcs. c) Histone 
modifications by ChIP-seq from ENCODE in the ETS1 CTS (highlighted in blue) in different cell lines. 
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Supplementary Figure S2. Analysis of CTCF binding to MYB gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for MYB gene in chromosome 6 from 5 human cell lines. CTCF binding 
site in the intron 1 of MYB gene is shown with a red arrow and CTCF binding site 37 kb upstream MYB gene is shown 
with an orange arrow. b) ChIA-PET interactions from the MYB CTS that are conserved are shown as red arcs and 
interactions that are not conserved are shown as blue arcs. c) Histone modifications by ChIP-seq from ENCODE in the 
MYB CTS (highlighted in blue) in different cell lines. 
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Supplementary Figure S3. Analysis of CTCF binding to HEY1 gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for HEY1 gene in chromosome 8 from 5 human cell lines. CTCF binding 
site in the exon 5 of HEY1 gene is shown with a red arrow. b) ChIA-PET interactions from the HEY1 CTS that are 
conserved are shown as red arcs and interactions that are not conserved are shown as blue arcs. c) Histone 
modifications by ChIP-seq from ENCODE in the HEY1 CTS (highlighted in blue) in different cell lines. d) ENCODE analysis 
showing CTCF binding site in the exon 5 of HEY1 in K562 cells, involving Hairy orange motif of HEY1, which is mutated 
in the arginine 123 in AML studies from cBioPortal.  
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Supplementary Figure S4. Analysis of CTCF binding to LMO2 gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for LMO2 gene in chromosome 11 from 5 human cell lines. CTCF binding 
site 34 kb downstream LMO2 gene is shown with a red arrow. b) ChIA-PET interactions from the LMO2 CTS that are 
conserved are shown as red arcs and interactions that are not conserved are shown as blue arcs. c) Histone 
modifications by ChIP-seq from ENCODE in the LMO2 CTS (highlighted in blue) in different cell lines. 
 
54 
 
 
Supplementary Figure S5. Analysis of CTCF binding to KLF1 gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for KLF1 gene in chromosome 19 from 5 human cell lines. CTCF binding 
site in the exon 2 of KLF1 gene is shown with a red arrow. b) ChIA-PET interactions from the KLF1 CTS that are 
conserved are shown as red arcs and interactions that are not conserved are shown as blue arcs. c) Histone 
modifications by ChIP-seq from ENCODE in the KLF1 CTS (highlighted in blue) in different cell lines. 
 
55 
 
 
Supplementary Figure S6. Analysis of CTCF binding to NFE2L2 gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for NFE2L2 gene in chromosome 2 from 5 human cell lines. CTCF binding 
site in the intron 1 of NFE2L2 gene is shown with a red arrow and CTCF binding site in the exon 1 of NFE2L2 is shown 
with an orange arrow. b) ChIA-PET interactions from the NFE2L2 CTS that are conserved are shown as red arcs and 
interactions that are not conserved are shown as blue arcs. c) Histone modifications by ChIP-seq from ENCODE in the 
NFE2L2 CTS (highlighted in blue) in different cell lines. 
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Supplementary Figure S7. Analysis of CTCF binding to TCF3 gene with UCSC Genome Browser. a) ENCODE analysis 
showing ChIP-seq profile of CTCF and Rad21 for TCF3 gene in chromosome 19 from 5 human cell lines. CTCF binding 
site 23 kb upstream TCF3 gene is shown with a red arrow. b) ChIA-PET interactions from the TCF3 CTS that are 
conserved are shown as red arcs and interactions that are not conserved are shown as blue arcs. c) Histone 
modifications by ChIP-seq from ENCODE in the TCF3 CTS (highlighted in blue) in different cell lines. 
 
 
 
 
 
 
 
 
 
 
 
